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Purpose: An acute dose of tyrosine, 1 hour before exercise has been associated with improved 
exercise capacity in a warm condition although the same dose has failed to demonstrate any 
benefit on exercise performance at the same environmental temperature. The present study 
sought to determine whether administering different doses of tyrosine across trials would 
demonstrate whether an optimal dose of tyrosine exists for improving exercise performance in 
the heat.  
 
 
Method: Following familiarisation, 8 healthy male volunteers who were unacclimated to 
exercise in the heat, performed 4 experimental trials at 30ºC/60% relative humidity, consuming 
one of four drinks (placebo, 150 mg kg body mass-1, 300 mg kg body mass-1 or 400 mg kg body 
mass-1) in a randomised crossover design, separated by at least 7 days. In the hour prior to 
exercise, participants consumed one of the four experimental drinks before exercising for 1 hour 
at 10% ∆ (129 ± 17 W) and then completing a simulated time trial as quickly as possible which 
required the completion of an individualised target work quantity (326 ± 37 kJ).  
 
 
Results: Time trial time (P= 0.553) and time trial power output (P = 0.281) remained similar 
across all trials. The plasma ratio of tyrosine: ∑LNAA was similar at rest between all trials (P = 
0.657) but increased significantly from rest in all tyrosine conditions (P < 0.01;). The tyrosine 
ratio increased 4.8 fold from baseline in LOW, 7.3 fold in MED and 7.3 fold in HIGH. Core 
temperature (P = 0.326), skin temperature (P = 0.127), heart rate (P > 0.05), Ratings of perceived 
exertion (P > 0.05) and thermal sensation (P > 0.05) also remained similar across all trials.  
 
 
Conclusion: The data demonstrates that acute administration of a range of tyrosine doses has no 
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Physical exercise in all mammals results in an increase in internal heat production and core 
temperature (Wednt, Loon and Marken Lichtenbelt, 2007). Humans have evolved a number of 
physiological mechanisms, such as vasodilation, vasoconstriction and sweating, in order to not 
only survive in warm temperatures, but to perform tasks effectively in high temperatures for 
prolonged periods of time. Despite this, it is well documented that prolonged exercise in the heat 
is significantly impaired in comparison to exercise in cooler conditions (Galloway and Maughan, 
1997; Febbraio, Snow, Stathis, Hargreaves and Corey, 1994; Tatterson, Hahn, Martin and 
Febbraio, 2000).   There is still much debate as to the precise mechanisms which cause fatigue 
during exercise, defined as “an increase in perceived effort required to exert a desired force or 
power output and the subsequent inability to produce that power output” (Davis and Bailey, 
1997). Exercise capacity is defined by Goldstein (1990) as the maximum amount of physical 
exertion that can be sustained at a given work intensity, while exercise performance is defined by 
Coyle (1999) as the amount of power or velocity that can be maintained over a set period of time.  
Central fatigue (fatigue within the central nervous system) or peripheral fatigue (fatigue outwith 
of the central nervous system), or a combination of both processes, have all been argued to be the 
primary influence on exhaustion during exercise. 
 
When the human body encounters increased heat stress, developed through metabolic heat, 
external heat or a combination of both, it responds in a number of ways to maintain thermal 
homeostasis and assist in delaying fatigue. These responses to heat stress are co-ordinated by the 
hypothalamus, an area of the brain responsible for maintaining thermoregulation. The 
hypothalamus plays a vital role in controlling body temperature by coordinating thermal 
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information from all areas of the body and directing the efferent signals to the appropriate heat 
production and heat conservation systems in mammals (Cooper, 2002). Changes in body 
temperature are detected by thermosensitive neurons, which have the ability to monitor the 
temperature of blood flowing into the brain and send feedback to the hypothalamus; effectively 
detecting changes in core temperature (Wednt, Loon and Marken, 2007). When challenged with 
an increasing body temperature, the hypothalamus will respond by initiating the processes of 
vasodilation and sweating. These are considered the primary peripheral mechanisms by which 
humans lose heat in high ambient temperatures or during exercise, in order to maintain thermal 
homeostasis.  The combination of exercise and high ambient temperatures poses a particularly 
challenging situation for human thermal physiology. 
 
Physical exercise results in an increased internal temperature and so therefore there is a 
simultaneous demand for blood from both skeletal muscle and the skin. This can pose a 
particular circulatory challenge when exercise is performed in the heat.  The need for an 
increased blood flow to the skin, especially at high core temperatures, is to facilitate heat 
exchange with the environment through evaporative sweat loss. The evaporation of sweat from 
the skin decreases skin temperature and subsequently lowers the temperature of the blood in the 
dilated vessels near the body’s surface before it returns to the core, slowing the increase in core 
temperature (Shirreffs, Aragon-Vargas, Chamorro, Maughan, Serratosa and Zachwieja, 2005); 
Charkoudian, 2003).  The effectiveness of the vasodilatory process is highlighted by the 
suggestion in the aforementioned study that skin blood flow can increase from 0.25 L·min-1 at 
rest to 8.00 L·min-1 during physical activity in warm environments. If the body is unable to 
match heat gain with heat dissipation, then temperature will begin to increase, which will 
eventually begin to impair exercise performance (Casa, 1999). A study by Gonzalez-Alonso et 
al., (1999) examined the influence of body temperature on fatigue during prolonged exercise.  
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The study found peripheral factors such as increased heart rate and reduced stroke volume 
contributed significantly to a shorter time to exhaustion when participants reached critical 
hyperthermia (40.1 – 40.2 ºC). 
 
It has been suggested that the ability of humans to exercise is limited by peripheral mechanisms 
such as metabolic and cardio-respiratory capacity (Kayser, 2003). Examples of this include 
diminishing substrate availability in working muscle, circulatory factors such as an attainment of 
peak oxygen uptake (V̇O2 peak) and an increasing concentration of blood lactate (Kayser, 2003). 
Other studies however, have suggested that fatigue in warm conditions exhibits a large central 
element. Nielsen, Hyldig, Bidstrup, Gonzalez-Alonso and Christoffersen (2001) observed 
alterations in the electrical activity of the brain’s frontal area measured via electrodes attached to 
the scalp, when subjects became hyperthermic during exercise in the heat. The study found that 
electrical activity in the prefrontal cortex increased initially from rest to the start of exercise 
before the high frequency β band began to gradually decline.  These changes are associated with 
reduced arousal. This occurred at the same time as a progressive increase in oesophageal 
temperature which continued to rise until exhaustion. The authors summarised that these changes 
indicated hyperthermia associated fatigue.  In a separate study using a similar method to measure 
prefrontal cortex electrical activity, Nybo and Nielsen (2001) observed changes to cerebral 
electroencephalography (EEG) which was correlated with increases in ratings of perceived 
exertion, when exercising in the heat (40˚C). Although there is a large body of evidence that 
demonstrates that there are various factors that can result in fatigue during exercise in the heat, it 
is stated by Kayser (2003) that all voluntary exercise starts and ends in the brain.    
 
The interaction between the brain neurotransmitters serotonin (5-hydroxytryptamine) and 
dopamine has been suggested to have a regulative role in the development of fatigue (Meeusen, 
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Watson, Hasegawa, Roelands and Piacentini, 2006). Dopamine, serotonin and noradrenaline are 
the principle neurotransmitters that regulate a number of functions within the central nervous 
system, which include motor control, cognition, emotion, memory processing, stress responses 
and endocrine regulation (Kobayashi, 2001). The original central fatigue hypothesis proposed by 
Newsholme, Acworth and Blomstrand (1987), was based solely on the action of serotonin and 
suggested that increased brain serotonergic activity may augment loss of drive and lethargy 
during prolonged exercise resulting in a reduction in motor unit recruitment and exercise 
performance. Prolonged exercise has been shown to increase free fatty acids in the blood. This 
results in an increase in blood free-tryptophan concentration, serotonin’s precursor, as free fatty 
acids displace tryptophan from its binding sites on albumin molecules in the bloodstream (Davis, 
1995). However evidence for the original fatigue hypothesis is mixed with pharmacological 
manipulation of serotonin proved successful for example by Blomstrand, Hassmen, Ek, Ekblom 
and Newsholme (1997), but unsuccessful by Varnier et al., (1994).  Conversely dopamine has 
been associated with increased motivation, arousal, memory, reward mechanisms and increased 
attention (Meeusen et al., 2006).  Davis and Bailey (1997) proposed a revised central fatigue 
hypothesis that a high ratio of brain dopamine: serotonin will assist in prolonging exercise and 
delaying fatigue, whereas when dopaminergic activity is reduced fatigue is precipitated by a loss 
of coordination and motivation. Burgess, Davis, Borg and Buggy (1991) demonstrated that rats 
were able to exercise for a longer period of time when they were able to self-stimulate the ventral 
tegmental, an area of the brain high in dopaminergic pathways. As a potent dopamine releaser, 
studies have also demonstrated improved exercise performance with amphetamine administration 
in humans (Chandler and Blair, 1980). The importance of high dopaminergic activity led various 
authors to pharmacologically manipulate catecholamine activity to assess the effect on exercise 
performance. Interestingly, it was found by Watson, Hasegawa, Roelands, Piacentini, Looverie 
and Meeusen (2005) that exercise in the heat was enhanced by acute administration of bupropion, 
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a dual dopamine/noradrenaline reuptake inhibitor, in humans, however there was no effect found 
when exercise took place within a temperate climate. The authors suggested a possible increase 
in the risk of heat illness due to bupropion’s ability to dampen or override inhibitory signals 
arising from the CNS to cease exercise due to hyperthermia and enable an individual to continue 
to maintain a high power output (Watson et al., 2005).   Hasegawa, Piacentini, Sarre, Michotte, 
Ishiwata and Meeusen (2008) demonstrated that exercise performance in the heat was improved 
in rats with bupropion administration via acute injection. Samples gathered directly from the 
preoptic area and anterior hypothalamus in the brain, using microdialysis, showed increased 
extracellular concentrations of dopamine and noradrenaline during exercise in the heat, 
especially with bupropion administration compared to the control group.  This is supported in an 
earlier study by Piacentini, Clinkers, Meeusen, Sarre, Ebinger and Michotte (2003) which found 
bupropion administration increased brain dopamine concentration in rats when measured via 
microdialysis. A study by Bridge, Weller, Rayson and Jones (2003) demonstrated that high 
dopaminergic activity in the brain can delay fatigue and improve exercise ability in the heat. 
Bridge et al., (2003) gave participants either buspirone (dual 5-HT1a receptor agonist and DA 
D2 receptor antagonist) or pindolol (5-HT1a receptor antagonist) before participants exercised in 
the heat until exhaustion. The provision of both buspirone and pindolol was used to indirectly 
assess the dopaminergic and serotonergic components of prolactin release. Blood prolactin 
concentration is often used as an indicator of dopamine and serotonin activity as the release of 
prolactin from the pituitary, and the subsequent presence of prolactin in the blood, is stimulated 
by serotonin but inhibited by dopamine. A positive relationship was found between exercise 
tolerance and the non-serotonergic component of prolactin response to buspirone. The authors 
concluded that improved exercise tolerance was most likely due to increased activity of 
dopamine in the hypothalamus. This is supported by Cordery, James, Peirce, Maughan and 
Watson (2016) which demonstrated increases in prolactin concentration following exercise were 
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attenuated with administration of the dopamine precursor L-DOPA. The conclusions drawn from 
these studies suggest that prolonged exercise in the heat may impose a specific demand on 
central dopamine systems which is not present in cooler environments and that pharmacological 
manipulation can influence this in both rats and humans.  
 
Based on the evidence that dopamine plays an important role in exercise tolerance in the heat, 
Tumilty, Davison, Beckmann and Thatcher (2011) suggested that any substance that has the 
ability to increase dopamine availability should prolong exercise in the heat. The study 
demonstrated that an acute dose of a nutritional dopamine precursor, tyrosine, was associated 
with an improvement in exercise capacity in the heat. Watson, Enever, Page, Stockwell and 
Maughan (2012), however, found that tyrosine had no effect on exercise capacity in the heat 
when providing participants with a similar dose and using a similar exercise protocol. Other 
studies by Tumilty, Davison, Beckmann and Thatcher (2014) and Coull, Chrismas, Watson, 
Horsfall and Taylor (2015) also both found tyrosine to have no effect on exercise performance in 
the heat. It is possible that the stress of the exercise protocol was insufficient to increase 
catecholamine metabolism or that the dose of tyrosine used in these studies was insufficient to 
maintain catecholamine metabolism due to depletion of precursor availability.   Evidently, the 
use of nutritional precursors in an attempt to influence central neurotransmitters has so far 
produced mixed results during exercise in the heat, and therefore further investigation is 
necessary.  Despite mixed results in exercise trials, the effects of such precursors have shown 
promising results on cognitive function, which is discussed in more detail below.  
 
The Blood-Brain Barrier  
Tyrosine, as well as other large neutral amino acids (LNAA), must cross the blood brain barrier 
in order to exert effects on catecholamine metabolism in the brain. The blood-brain barrier is a 
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semi-permeable barrier which impedes influx of most compounds from the blood to the brain. 
There are three cellular elements of the brain’s microvasculature which compose the blood brain 
barrier – endothelial cells, astrocyte end feet and pericytes (Ballabh, Braun and Nedergaard, 
2004). Pachter, de Vries and Fabry (2003) state that the blood-brain barrier provides both 
anatomical and physiological protection for the central nervous system, strictly regulating the 
entry of many substances and blood borne cells into the nervous tissue. Entry of amino acids and 
other metabolites into the brain, which circulate within the blood and compete for uptake, takes 
place through the blood brain barrier. Tyrosine, tryptophan and phenylalanine (tyrosine 
precursor) all share a LAT-1 transporter with other LNAA (Oldendorf and Szabo, 1976). The 
competition for uptake at the blood-brain barrier is highlighted in a study by Fernstrom and 
Wurtman (1972).  This examined the effect of whether feeding protein in varying amounts would 
increase tryptophan uptake into the brain. Rats were provided with either a meal containing an 
amino acid mixture containing LNAA or a meal minus tryptophan’s suspected transport 
competitors, including tyrosine, phenylalanine, leucine, isoleucine, valine. It was reported that 
the rats who consumed the meal which lacked the suspected transport competitors displayed 
significant rises in brain tryptophan and serotonin synthesis. Despite large rises in plasma 
tryptophan concentration following the amino acid mixture meal, the increase was offset at the 
transport sites by a comparable and proportional increase in the plasma levels of tryptophan’s 
competitors (Fernstrom and Wurtman, 1972). Importantly, the meal lacking LNAA increased the 
blood ratio of tryptophan: LNAA. This is important as the blood ratio of an individual amino 
acid: amino acids competing for brain uptake is a key determinant of transport into the brain.  
Therefore, brain uptake of an individual amino acid can be increased by acutely increasing the 
blood concentration of that amino acid, or by reducing the concentration of amino acids 
competing for uptake (in both cases this would increase the blood ratio: competing amino acids).  
This is supported by experimental data in rats.  Fernstrom and Faller (1978) demonstrated that 
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the concentration of branched chain amino acids (BCAA) (valine, leucine and isoleucine) 
changes rapidly in the brain following the ingestion of a meal. Ingestion of a meal with 0% 
protein was shown to significantly increase levels of brain tryptophan, in parallel with a rise in 
serum tryptophan, compared to a meal containing either 18% or 40% protein. Despite significant 
increases in serum tryptophan following ingestion of the 18% and 40% protein rich meals, brain 
tryptophan concentration did not increase.  This was due to proportionally similar increases in 
blood concentrations of competing LNAA, with little change in the ratio of blood tryptophan: 
LNAA (Fernstrom and Faller, 1978).  Mauron and Wurtman (1982) demonstrated in rats that 
when a 3 g·kg-1 dose of glucose was administered alongside tyrosine, the ratio of serum tyrosine: 
LNAA and brain tyrosine concentration increased. The increase in brain tyrosine concentration 
can be attributed not only to the additional tyrosine but also to the glucose mediated insulin 
release which works to lower blood LNAA concentrations via uptake in peripheral tissues 
(Mauron and Wurtman, 1982).  When the concentration of a particular amino acid increases in 
the brain, there may be a subsequent increase in that amino acid’s neurotransmitter under suitably 
demanding conditions. Brady, Brown and Thurmond (1980) displayed significant increases in 
both brain tyrosine and dopamine in mice following tyrosine administration. Similarly, 
administration of tyrosine has been shown to increase dopamine release in rats in a study by 
Acworth, During and Wurtman (1988).  This study demonstrated that tyrosine caused a dose-
related increase in brain extracellular fluid dopamine levels, measured using brain microdialysis.  
 
Monoamine and Catecholamine Synthesis   
Tryptophan and tyrosine are considered to be unique among amino acids in being precursors to 
brain neurotransmitters (Fernstrom, 2013). Variations in the brain concentrations of tryptophan 
and tyrosine affect the synthesis and release of their respective neurotransmitters. Increasing 
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concentrations of brain tryptophan generally result in increased brain serotonin synthesis. 
Increased brain tyrosine concentration may result in greater synthesis of the brain 
neurotransmitters dopamine, norepinephrine (and epinephrine, less so) but only under suitably 
demanding conditions which increase the firing rates of catecholamine neurons. (Fernstrom, 
2013). Serotonin is synthesised from tryptophan using a two-step process, beginning with 
hydroxylation. Serotonin is produced by decarboxylation of 5 – hydroxytryptamine before 
serotonin is released from nerve terminals to interact with serotonin receptors on adjacent 
neurons (Fernstrom, 1983). Rapid transmission of the neurotransmitter then occurs across the 
synaptic cleft via a serotonin transporter before serotonin is either stored or metabolized 
(Fernstrom, 1983). Tyrosine and phenylalanine are considered to be the major precursors for the 
synthesis of dopamine and norepinephrine and can be found in abundance in natural dietary 
proteins (Elsworth and Roth, 1997). Blood-borne tyrosine is taken up into the brain where it is 
then transported from brain extracellular fluid to dopaminergic neurons by amino acid 
transporters (Elsworth and Roth, 1997).  The primary stage in the synthesis of these monoamines 
requires the addition of a hydroxyl group to the aromatic ring of tyrosine or the indole nucleus of 
tryptophan (Gibson and Wurtman, 1976). This process is catalysed by tyrosine hydroxylase and 
tryptophan hydroxylase, respectively, resulting in the creation of the hydroxylated products 
dihydroxyphenylalanine (DOPA) and 5-hydroxylated tryptophan. These are then both 
decarboxylated in separate neuron populations to form dopamine and serotonin (Gibson and 
Wurtman, 1976). To form noradrenaline, dopamine is β-hyrdroxylated by dopamine β-
hydroxylase. Noradrenaline is a key modulator of stress response in mammals and therefore, 
tyrosine, as a precursor, should prevent norepinephrine depletion and therefore maintain its 
synthesis during rapid neuronal firing. In order to produce adrenaline, noradrenaline is 




Evidence from previous studies demonstrates that tyrosine supplementation is more effective in 
increasing the synthesis and release of catecholamines if catecholamine neurons fire at an 
increased rate. This is linked to the underlying biochemical mechanisms controlling brain 
catecholamine synthesis.  At basal levels, tyrosine hydroxylase tightly controls dopamine 
synthesis. Increased dopaminergic neuronal firing as a result of stress exposure in rats, such as 
cold stress, tail shock, heat stress or forced swim stress, may deplete brain dopamine as a result 
of depleted precursor availability in some neuronal populations (Fernstrom, 1983). Additional 
tyrosine availability in such conditions assists in maintaining catecholamine turnover and may 
work to maintain or prevent the decline performance in demanding conditions.  For example, 
additional tyrosine can increase dopamine synthesis and release depending on the firing rates of 
nigrostriatal dopaminergic neurons in rats (Melamed, Hefti and Wurtman, 1980). Mice exposed 
to cold swim stress demonstrated decreased levels of dopamine although this decline was 
alleviated by tyrosine administration (Brady et al., 1980) suggesting tyrosine maintained 
catecholamine turnover during stress exposure. During, Acworth and Wurtman (1988) 
demonstrated an enhanced effect of tyrosine on dopamine release following partial lesioning of 
nigrostriatal neurons, but only in surviving neurons. Therefore, additional tyrosine availability in 
such conditions assists in maintaining catecholamine turnover. Based on this, it is plausible to 
suggest that precursor availability is a major limiting factor in catecholamine production, but 
only under very demanding conditions which sufficiently upregulate brain catecholamine 
function (Fernstrom, 1983). In conditions which do not suitably stress dopaminergic neurons, 
any additional tyrosine is likely to be affected by end-product inhibition of tyrosine hydroxylase. 
This is demonstrated by Badaway and Williams (1982) who found that when rats were provided 
with a 25 mg·kg-1 tyrosine they displayed increases in catecholamine synthesis but when 
administered with > 50 mg·kg-1 tyrosine, there was no such increase. Given that the rats were 
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unstressed (i.e. no specific experimental stress protocol was present) it is perhaps unsurprising 
that the larger dose of tyrosine failed to increase catecholamine synthesis. 
 
Catecholamines and Prolonged Exercise in the Heat  
The original central fatigue hypothesis was based upon the actions of serotonin, with the 
assumption that the increased presence of serotonin during exercise will augment loss of drive, 
lethargy and result in a decreased level of performance. This original hypothesis has since been 
developed and now encompasses the synthesis and metabolism of catecholamines, such as 
dopamine and noradrenaline to form the basis of the revised central fatigue hypothesis (Meussen 
et al., 2006). Evidence also suggests that dopamine may be implicated in thermoregulation 
during exercise, in rat (Hasegawa, Piacentini, Sarre, Michotte, Ishiwata and Meeusen, 2008) and 
human studies (Watson et al., 2005).   
  
Hasegawa et al., (2008) examined how brain catecholamines influenced the development of 
fatigue in rats during exercise in the heat. The aim of the study was to identify if there was any 
effect on exercise performance following an acute injection of bupropion. The study also 
monitored the effects of bupropion on thermoregulation and neurotransmitter activity in the 
anterior hypothalamus and preoptic area in the rat during exercise via a microdialysis probe. The 
rats exercised to exhaustion in three trials, in 30˚C with either bupropion or saline as placebo and 
at 18˚C. The results demonstrated time to exhaustion was significantly higher in the heat 
following intake of bupropion despite significantly higher core and brain temperatures compared 
to exercise in the heat with placebo. Extracellular levels of dopamine and noradrenaline 
increased during exercise, but were significantly higher in the group who were administered the 
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bupropion, suggesting that an increased level of dopamine and noradrenaline in the preoptic area 
and anterior hypothalamus may be responsible for an increase in exercise performance.   
 
A study by Watson et al., (2005) reported that acute administration of bupropion, a dual 
dopamine/noradrenaline reuptake inhibitor, resulted in improved exercise performance in the 
heat but not in a temperate condition, suggesting there may a specific demand for dopamine 
during exercise in the heat.  Here it was proposed that bupropion acted on dopamine 
neurotransmission to maintain motivation and arousal and allowed subjects to overcome fatigue 
sensation. Bridge et al., (2003) also found time to exhaustion was positively influenced by 
dopaminergic pathways when participants were administered either buspirone or pindolol, the 
provision of which was used to indirectly assess the dopaminergic and serotonergic components 
of prolactin release. The study found a correlation between time to exhaustion and the non-
serotonergic component of prolactin response to buspirone administration.  Similarly to Watson 
et al., (2005), work by Roelands et al., (2008a) examined how a dopamine reuptake inhibitor 
affected exercise performance and thermoregulation during exercise in both hot and temperate 
conditions. Eight male subjects consumed a placebo or a dose of ritalin, an amphetamine-like 
agent containing methylphenidate, prior to exercise in either a warm condition (30˚C) or a 
temperate condition (18˚C). Ritalin has a high affinity for the dopamine transporter, which 
inhibits the reuptake of neuronal dopamine within the brain. Participants were required to cycle 
for sixty minutes at 55% Wmax (55% of the total watts achieved during a preliminary maximal 
exercise test) which was immediately followed by a time trial, equivalent to the amount of work 
equal to 30 minutes of exercise at 75% Wmax, to assess exercise performance.  It was found that 
participants who ingested ritalin prior to exercise in the heat performed the time trial 16% faster 
compared to the placebo group. However, exercise in the temperate climate was unaffected by 
ritalin ingestion, demonstrating once more that brain dopamine availability positively influenced 
13 
 
exercise tolerance in the heat. Another study by Roelands et al., (2008b) (using the same exercise 
protocol described above) demonstrated that norepinephrine reuptake inhibition via oral 
administration resulted in decreased exercise performance in temperate and warm conditions. 
This was accompanied by increased heart rate and increased subjective feelings of cold with 
norepinephrine reuptake inhibition, which may have negatively affected exercise performance. 
Norepinephrine’s association with serotonin synthesis suggests that serotonin neurotransmission 
was potentially increased with norepinephrine reuptake inhibition. Norepinephrine neurones 
modulate the serotonin system via excitatory1-adrenoceptors (Roelands et al., 2008b). These 
studies provide persuasive evidence that increased dopamine availability through administration 
of reuptake inhibitors and amphetamine can improve exercise performance in the heat. It is also 
evident that there may be specific demand for dopamine in the heat which is not present during 
exercise in temperate conditions.  
 
Nutritional Manipulation of Central Monoamines in Animals and Humans  
(See summary table 1) 
Serotonin’s association with fatigue has led a number of studies to examine the effects of 
nutritional and pharmacological manipulation of serotonin in both animals and humans through a 
variety of means. Soares, Coimbra and Marubayashi (2007) found that when tryptophan was 
injected directly into the lateral cerebral ventricle area of the brain in rats, exercise fatigue 
occurred more rapidly compared to when a saline solution was administered.  Other studies in 
rats generally confirm that pharmacological manipulation of brain serotonin impairs performance 
(Bailey, Davis and Ahlborn 1992; Bailey, Davis and Ahlborn, 1993), although results are 
somewhat mixed in humans (Pannier, Bouckart and Lefebvre, 1995; Piacentini Meeusen, Buyse, 
De Schutter and De Meirleir, 2002a).  Investigations have administered branched chain amino 
acids in order to assess the effects on brain serotonin and exercise performance, many of which 
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have produced mixed findings. In one study, Choi, DiSilvio, Fernstrom and Fernstrom (2013) 
examined whether oral administration of BCAA to rats would reduce both serotonin and 
catecholamine synthesis through decreases in brain tryptophan and tyrosine. The study 
demonstrated that BCAA administration did reduce serotonin and catecholamine synthesis 1 hour 
after BCAA intake. However, earlier work by Verger, Aymard, Cynobert, Anton and Luigi 
(1994) demonstrates that when rats were administered BCAAs, they fatigued quicker during 
prolonged treadmill running compared when either water or glucose was provided, 
demonstrating that results in rats are mixed.   Blomstrand et al., (1997) examined whether the 
acute intake of BCAA in humans would prevent the increase in free tryptophan, reduce brain 
uptake of tryptophan and thus delay fatigue. Seven male participants performed two bouts of 
exhaustive exercise on a cycle ergometer after performing a bout of exercise the previous day at 
70% V̇O2peak. This was followed by 20 minutes of maximal exercise designed to deplete muscle 
glycogen stores. Participants received either BCAA or placebo during each trial. They found that 
ingestion of a BCAA solution was associated with an improved mental performance and a 
reduction in rating of perceived exertion (RPE) during the bout of prolonged exercise. 
Furthermore, it was reported that the ratio of the plasma concentration of tryptophan: BCAA was 
significantly increased in the placebo trial in comparison to the BCAA trial.  This demonstrated a 
link between the reduced ratio of blood tryptophan to BCAA, an improved mental performance 
and a reduction in the subjective perception of work. There are, however, other studies which 
have failed to find any performance enhancing effect of BCAA administration during exercise 
while studies examining tryptophan administration have produced mixed results. Varnier et al., 
(1994) found no differences in exercise performance when participants were provided with either 
20 g of BCAA or saline, 70 minutes prior to a graded incremental exercise bout to exhaustion. 
Furthermore, Davis, Alderson and Welsh (2000) found BCAAs to have no effect on exercise 
capacity, RPE or cardiovascular and metabolic function during exercise to fatigue at 70% V̇O2 
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max. The weight of evidence from the literature suggests that administration of BCAA generally 
does not enhance exercise performance or delay fatigue in humans, despite a sound physiological 
basis for the intervention (Davis, Alderson and Welsh, 2000).   
 
A number of studies have also found that other forms of pharmacological manipulation of brain 
serotonin have had no effect on exercise performance in humans. Pannier et al., (1995) found 
that, despite administration of the antiserotonin agent pizotifen, a 5-HT receptor antagonist, 
exercise performance did not improve. They found that performance level was lower when 
pizotifen was administered in comparison to placebo. Studies by Piacentini et al., (2002a) and  
Piacentini, Meeusen, Buyse, De Schutter, Kempenaers, Van Nijvel, and De Meirleir (2002b) 
both found no effect on performance when venlafaxine, a serotonin/noradrenaline reuptake 
inhibitor and  reboxetine, a noradrenergic reuptake inhibitor, respectively, were administered to 7 
well trained male cyclists. Despite finding no effect on exercise performance, both studies did 
discover increased neurotransmitter activity in response to drug administration demonstrating a 
possible central effect. Segura and Ventura (1988) examined how supplementing tryptophan 
would affect exercise performance. Following two trials, where participants exercised at a 
workload of 80% V̇O2 max with ingestion of either tryptophan or a placebo, it was found that 
exercise time was 49.4% greater with tryptophan ingestion in comparison to placebo. This is 
somewhat surprising given the proposed effects of serotonin on the brain and the influence on 
fatigue processes.  This also highlights the mixed results in studies which have manipulated 
serotonin levels using various forms of dietary means.  Strensrud, Ingier, Holm and Stromme 
(1992) conducted a similar study, and provided participants with either tryptophan or placebo to 
ascertain whether the results would be replicated. Following two trials to exhaustion, with either 
the tryptophan supplement or a placebo, it was found that there was no significant difference 
between the two trials. This emphasised that supplementation of tryptophan did not enhance 
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running performance, raising questions about the results produced by the original study by 
Segura and Ventura (1992). This led these authors, and others (Davis et al., 1992) to conclude 
that, the hypothesis that a central component to fatigue which apparently exists during prolonged 
exercise, is not primarily mediated by serotoninergic neurons. 
 
The discrepant findings within the literature in relation to the original central fatigue hypothesis 
suggests that central serotonin function cannot be acutely manipulated by dietary or 
pharmacological intervention, despite some evidence of altered brain neurotransmitter function in 
some studies.  Many studies then focussed their attention on central dopamine as a candidate for 
dietary manipulation.  These studies adopted the revised central fatigue hypothesis suggested by 
Davis and Bailey (1997). 
17 
 
Table 1. Summary of studies examining effects of nutritional and pharmacological manipulation of neurotransmitters in vivo 
(See Table 2 for tyrosine studies) 
Animal Studies 
Authors Animal Treatment Protocol Main findings 
Choi et al., (2013) Male Sprague-Dawley 
rats  
BCAA / BCAA + 
Tyrosine 
Sedentary and exercising 
rats provided treatment. 
Sacrificed 60 minutes after 
treatment ingestion. 
BCAA reduced brain tryptophan and 
tyrosine concentrations. Lowered 
serotonin and catecholamine synthesis.  
Reductions in tyrosine concentration 
and catecholamine synthesis following 
BCAA intake can be reduced by co-
administering tyrosine. 
Hasegawa et al., 
(2008) 




Running to exhaustion at 
26 m·min-1 at 30˚C and 
18˚C. 
Running time to exhaustion in the 
heat was increased with bupropion. 
Extracellular concentrations of 
dopamine and noradrenaline 
significantly higher with bupropion. 
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Piacentini et al., 
(2003) 




Samples for serotonin, 
dopamine, and 
norepinephrine were 
collected every 20 min 
before and after the 
injection of 17 mg·kg-1 of 
bupropion for 180 mins. 
Dopamine, noradrenaline and 
serotonin all increased after 
bupropion administration. 
Accompanied by decreased 
prolactin concentration.  
Verger et al., 
(1994) 
34 male Wistar rats  BCAA, Glucose, Water Running time to 
exhaustion.  
Running time to exhaustion was 
highest following glucose 
administration. Rats fatigued 









Authors Population Treatment Protocol Main findings 
Bridge et al., 
(2003) 
 





0.5 mg·kg body mass-1 
Buspirone alone, or in 
conjunction with 0.5 
mg·kg body mass-1 
pindolol 
Cycling at 73% V̇O2 max 
until exhaustion at 35˚C. 
Correlation between time to 
exhaustion and the non-serotonergic 
component of prolactin response to 
buspirone. 
Cordery et al., 
(2016) 
10 physically active 
males 
100 mg L-DOPA/25 mg 
carbidopa 
1 hour cycling at 60% V̇O2 
max followed by a 30 
minute exercise test + 
finger tapping test and 
start and end of exercise. 
No performance effect. Increasing 
catecholamine availability inhibits 
prolactin response.  
Greer et al., (2011) 9 untrained males  200 kcal of either BCAA, 
Carbohydrate or Placebo 
3 x 90 minute bouts of 
exercise (per treatment) at 
55% V̇O2 max followed by 
a 15 minute Time Trial. 
CHO ingestion resulted in the 
greatest distance covered during the 
TT. BCAA had no effect. BCAA 
did positively affect RPE. 
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Pannier et al., 
(1995) 
8 healthy men 1 mg serotonin receptor 
antagonist pizotifen 
Running at 70% V̇O2 max 
until exhaustion. 
No effect of pizotifen on exercise 
capacity. 
Piacentini et al., 
(2002a) 
7 well trained male 
cyclists  
2 x 37.5 mg of venlafaxine 
 
Cycling time trial  No effect of serotonin/noradrenaline 
reuptake inhibitor on exercise 
performance. 
Piacentini et al., 
(2002b) 
7 well trained male 
cyclists 
2 x 4 mg selective 
noradrenergic reuptake 
inhibitor   reboxetine  
Endurance time trial  Performance unaffected by 
reboxetine.  
Roelands et al., 
(2008) 
8 healthy well trained 
males 
20 mg dopamine reuptake 
inhibitor ritalin 
Cycling for 60 minutes at 
55 Wmax followed by time 
trial at 18˚C and 30˚C. 
Ritalin improved exercise 
performance at 30˚C but not 18˚C.  
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Roelands et al., 
(2008) 
9 healthy well trained 
males  
2 x 8 mg Reboxetine  Cycling for 60 minutes at 
55 Wmax followed by 
time trial at 18˚C and 
30˚C. 
Norepinephrine reuptake inhibition 
reduced exercise performance in 
temperate and warm conditions. 
Roelands et al., 
(2009) 
8 healthy well trained 
males 
150 mg bupropion for 3 
days following by 300 mg 
for 7 days.  
Cycling for 60 minutes at 
55 Wmax followed by 
time trial at 18˚C and 
30˚C. 
Bupropion increased circulating 
growth hormone levels. No effect of 
chronic bupropion administration 
on exercise performance.  
Segura and 
Ventura (1988) 
12 healthy sportsmen 4 x 150 mg tryptophan  Running to exhaustion at 
80% V̇O2 max.  
Exercise time was 49.4% longer 
following tryptophan ingestion. 
Perceived exertion was lower with 






Strensrud et al., 
(1992) 
49 well trained male 
runners 
Total of 1.2 g tryptophan 
administered over 24 
hours prior to exercise 
bout. 
Running to exhaustion at a 
speed corresponding to 
100% V̇O2 max. 
Tryptophan had no significant 
effect on time to exhaustion 
compared to placebo. 
Strüder et al., 
(1998)  
10 males  21 g BCAA, 20 g tyrosine, 
20 mg paroxetine.  
Cycling time to 
exhaustion.  
BCAAs and Tyrosine had no effect 
on time to exhaustion. Time to 
exhaustion was lower with 
paroxetine. 
Watson et al., 
(2006) 
9 healthy endurance 
trained males 




Cycling for 60 minutes at 
55 Wmax followed by 
time trial at 18˚C and 
30˚C. 
Bupropion improves exercise 




Tyrosine Supplementation, Behaviour and Cognitive Performance  
(See summary table 2) 
Animal Studies 
There are a number of studies which have examined the effects of tyrosine administration on 
cognitive function in both animals and humans. Many of these studies provide evidence that 
tyrosine increases catecholamine metabolism under conditions of increased stress with 
maintenance, or the prevention of stress-induced declines, demonstrated in various cognitive 
performance measures.   
 
Brady, Brown and Thurmond (1980) provided tyrosine to rats to assess its effect on aggressive 
behaviour, locomotor activity and brain neurochemistry following cold swim stress. Tyrosine 
administration increased aggressive behaviour in young, non-stressed mice while increasing 
levels of brain tyrosine and dopamine in both young and old mice. Tyrosine also prevented the 
decrease in locomotion in older stressed and non-stressed mice.   Supplementation of tyrosine 
was found to be effective in reducing the effects of stress which induced an increased 
catecholamine metabolism (Brady, Brown and Thurmond, 1980).   
 
Stress induced by tail shock was used by Lehnert, Reinstein, Strowbridge and Wurtman (1984) to 
assess tyrosine’s effect on norepinephrine turnover, a key modulator in the stress response of 
mammals, and behavioural deficits in rats. Rats were provided with either a control diet or diets 
enriched with tyrosine or tyrosine + valine before exposure to tail shock or a controlled 
environment. Exposure to stress caused increased norepinephrine turnover resulting in 
norepinephrine depletion in some neurons. Behavioural deficits in rats were examined using 
measures of locomotion and exploration in an open field environment (Lehnert et al., 1984). 
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Stressed rats displayed less exploration activity and spontaneous motor activity during the 
locomotion compared to control rats. Rats who received tyrosine did not display behavioural 
deficits nor a stress induced depletion in norepinephrine. However, rats who received tyrosine + 
valine did not demonstrate the same preventative effects as the tyrosine only group.  This makes 
sense considering that valine competes with tyrosine for transport across the blood brain barrier 
(Lehnert et al., 1984). It was also observed that when tyrosine was administered to rats not 
subjected to stress, there was no increase in norepinephrine turnover or behavioural responses. 
This evidence demonstrates that tyrosine prevents norepinephrine depletion and prevents 
behavioural deficits but only when catecholaminergic neurones are considerably more active as a 
result of stress exposure.  Reinstein, Lehnert, Scott and Wurtman (1984) confirmed these results 
using a similarly designed study, once again finding tyrosine administration enhanced 
catecholamine synthesis and prevented behavioural deficits during stress exposure through tail 
shock.  
 
Shurtleff, Thomas, Ahlers and Schrot (1993) administered 50, 100 or 200 mg·kg-1 of tyrosine to 
eight rats to assess its effect on cognitive performance in a matching sample task. It was 
hypothesised that tyrosine supplementation would assist in preventing a deficit in brain 
catecholamine levels when exposed to acute environmental stress.  The protocol involved the 
administration of one of the tyrosine doses or a saline solution (placebo) to the eight rats before 
the requirement to perform a delayed matching to samples task, within a temperature of either 
22˚C or 2˚C.   It was found that the higher doses of tyrosine (100 g and 200 g) were associated 
with improved cognitive performance during cold exposure in comparison to the lower 50 g dose 
and the placebo, demonstrating a possible dose-response effect. Specifically, it was found that 
matching accuracy was significantly improved and errors were significantly decreased in the cold 
at the higher tyrosine doses of 100 and 200 mg·kg-1. It was however found that while the higher 
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doses of tyrosine improved matching accuracy and reduced error rate in the cold, the results 
remained significantly decreased in comparison to those in the 22˚C trial. It was concluded that 
improvements in the cold exposure trial were due to the amelioration of the deficit of brain 
catecholamine levels as a result of tyrosine administration.  
 
The effect of tyrosine administration on behaviour in cold stressed rats was examined by 
Yeghiyayan, Luo, Shukitt-Hale and Lieberman (2001). Rats were given tyrosine, amphetamine 
or phenylpropanolamine (an adrenoceptor agonist) alone or combinations of amphetamine or 
phenylpropanolamine + tyrosine to assess how tyrosine potentiates the drugs during 30 minute 
cold exposure and a subsequent swimming test. The study demonstrated that all three treatments 
improved performance and tyrosine + drug combinations further enhanced performance 
compared to single drug administration. Tyrosine also elevated brain norepinephrine 
concentration in rats stressed by hypothermia compared to rats treated with a saline solution.  
 
Lieberman, Georgelis, Maher and Yeghiayan (2005) administered 400 mg·kg body mass-1 
tyrosine intraperitoneally to rats to assess its effect on norepinephrine synthesis during heat 
exposure (41ºC). Memory and coping behaviour were assessed using a standardised maze and 
swim test respectively. Hippocampal dopamine and norepinephrine were also assessed using 
microdialysis. The study found that heat impaired coping and memory in vehicle treated rats and 
increased the release of norepinephrine.  In rats treated with tyrosine, coping was not impaired 
and tyrosine sustained norepinephrine release as heat stress increased, demonstrating tyrosine to 
have a protective effect, through sustained norepinephrine release, during exposure to heat stress.  
 
These studies demonstrate that tyrosine supplementation in rodents has a beneficial effect on in 
vivo behaviour, cognitive function and brain catecholamine synthesis across a range of different 
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environmental stressors.  
 
Human Studies  
Prior to a number of studies examining the effects of tyrosine administration on both exercise 
capacity and performance as well as cognitive function, Glaeser, Melamed, Growdon and 
Wurtman (1979) demonstrated the effect of a single dose of tyrosine on plasma tyrosine 
concentration without an exercise protocol. Administration of either 100 mg·kg body mass-1 or 
150 mg·kg body mass-1 produced increases in the tyrosine concentration from 69 to 154 
nmols·ml-1 and to 203 nmols·ml-1, respectively, 2 hours after ingestion. The tyrosine ratio, 
described in the study as the ratio of plasma tyrosine concentration to the sum of the 
concentrations of six other amino acids that compete for the same blood barrier uptake carrier 
(Glaser et al., 1979) increased from 0.10 to 0.28 in the 100 mg·kg-1 dose and to 0.35 in the 150 
mg·kg-1 dose. Manipulation of amino acid ratios has also been demonstrated in previously 
mentioned study by Fernstrom and Wurtman (1972) which increased the ratio of tryptophan to 
competing amino acids, including tyrosine. 
 
Similarly to animal studies, when tyrosine has been provided to human subjects, there appear to 
be improvements in cognitive function while exposed to stressful environments. Banderet and 
Lieberman (1989) provided 100 mg·kg body mass-1 tyrosine to twenty three males prior to a 4.5 
hour exposure to cold and hypoxia in a randomised crossover design. Tyrosine administration 
significantly reduced adverse emotions resulting from the environmental conditions. Tyrosine 
also improved vigilance, pattern recognition and reaction time. The study also demonstrated that 





Neri, Wiegmann, Stanny, Shappell, McCardie and McKay (1995) examined the behavioural 
effects of tyrosine during an episode of continuous work with a night of sleep loss. Twenty 
subjects performed a battery of performance tasks and mood scales for approximately 13 hours 
(Neri et al., 1995). All participants remained awake on the day testing began and by the end of 
testing had been awake for greater than 24 hours. 6 hours into the experiment and in a double-
blind fashion, half of the subjects received a dose of 150 mg·kg body mass-1 tyrosine while the 
other half received a placebo. Tyrosine administration was shown to ameliorate the performance 
decline on a psychomotor task and demonstrated a reduction in lapse probability on a high event 
rate vigilance task (Neri et al., 1995) demonstrating tyrosine to be successful in preventing 
performance decrements during sustained work and sleep loss (Neri et al., 1995).  
 
Deijen, Wientjes, Vullinghs, Cloin and Langefeld (1999) studied the effects of tyrosine on 
cognitive task performance. The participants used were all cadets who were involved in a 
demanding military combat training course. Out of the twenty one participants who were taking 
part in the study, ten received five daily doses of a protein-rich drink each of which contained 2 g 
of tyrosine. The remaining eleven subjects received a similar drink containing carbohydrate with 
a similar number of calories, but no tyrosine.  Cognitive assessments were made prior to the 
beginning of the course and then on the sixth day. The results demonstrated that the group 
supplied with the drink containing tyrosine performed better on a memory and tracking task 
compared to the carbohydrate group when assessed on the sixth day of the course. A limitation, 
however, lies with the carbohydrate drink, which was acknowledged by the study as not a ‘real 
placebo’. The macronutrient content of the drink may have resulted in increases in the blood ratio 
of LNAA: tyrosine, which may have increased synthesis of serotonin and release (Deijen et al., 
1998). It has been previously mentioned that carbohydrate, via insulin release, can lower the 
concentration of blood amino acids and therefore increase the tryptophan: LNAA ratio (Deijen et 
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al., 1998). Despite this, the study concluded that ingestion of tyrosine under operational 
circumstances may assist in reducing the effects of stress and fatigue in cognitively demanding 
situations.   
 
A study by Mahoney, Castellani, Kramer, Young and Lieberman (2007) used 19 participants to 
determine if tyrosine supplementation could improve human cognition when exposed to cold 
stress. Participants completed three trials on different days which required the completion of two 
90-minute water immersions during each trial. Before each immersion, participants consumed a 
food bar which contained either 150 mg·kg body mass-1 of tyrosine (300 mg·kg body mass-1 
total) or a placebo. The three immersion states were 35˚C/control, 10˚C/placebo and 
10˚C/tyrosine. During each trial, cognitive performance, mood and salivary cortisol were 
recorded. The study discovered that the cold water immersion resulted in a drop in cognitive 
performance although supplementation of tyrosine assisted in alleviating working memory 
decrements. 
 
Lieberman et al., (2014) examined whether tyrosine prevents the decline in cognitive ability in 
response to severe levels of stress induced by mock interrogations during a period of simulated 
captivity. The study recruited 78 male and female military personnel to participate who were 
administered either 300 mg·kg body mass-1 of tyrosine or placebo. Tyrosine was administered 
via two food bars each containing 150 mg·kg body mass-1 sixty minutes before participants were 
required to withstand a mock interrogation. Heart rate, saliva cortisol and mood (via profile of 
mood states questionnaire) were all recorded. The study found that tyrosine had no effect on the 
majority of responses to stress although it did demonstrate that supplementation of tyrosine 
increased ratings of anger. The study suggests that the feeling of anger may be an appropriate 
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response to stressful situations. For example, interrogations have been associated with a loss of 
control and optimism in healthy adults when they are exposed to stressful situations (Lerner et 
al., 2007). This led to the conclusion that increased feelings of anger, brought about by tyrosine 
supplementation, may represent a coping mechanism to deal with stressful situations more 
effectively. 
 
Coull et al., (2015) examined whether a 150 mg·kg body mass-1 dose of tyrosine would affect the 
cognitive and physical performance of eight male soccer players exercising in the heat. The 
implication was that exercise in the heat would be sufficiently stressful to increase the demands 
for brain tyrosine.  The protocol involved each participant completing an individualised 90-
minute simulated soccer performance test. This test was completed on two separate occasions in 
a temperature of 25˚C and 60% relative humidity, once with the tyrosine dose and the other with 
a placebo. Mental effort and vigilance were also assessed. Participants were required to complete 
a dual task test with the requirement of tracking a moving target with the mouse cursor whilst, 
simultaneously, responding to varying stimuli with the spacebar. It was found that vigilance 
improved significantly with hit responses increased by 9 ± 28% and miss responses decreased by 
31 ± 29% with tyrosine administration compared to placebo. The results suggested that tyrosine 
may have a positive effect on cognitive performance during exercise. A minor criticism of this 
study is that the protocol took place at an environmental temperature of 25˚C; however, their data 
report that subjects were hyperthermic. 
 
These studies provides evidence that tyrosine, in general, is an effective nutritional supplement in 
improving cognitive function when performing tasks in a wide variety of stressful environments, 




Tyrosine Supplementation Alone and in Conjunction with Exercise 
(See summary table 2) 
 
Studies in which humans were administered tyrosine to assess its effect on exercise performance 
and capacity have produced mixed results. Strüder, Hollman, Platen, Donike, Gotzmann and 
Weber (1998) conducted a study to assess the effects of 20 mg of paroxetine (serotonin reuptake 
inhibitor), 21 g of BCAA, 20 g of tyrosine or a placebo on constant load submaximal exercise to 
exhaustion in cyclists. Administration was carried out in a randomised, double-blind fashion, 
across four separate exercise trials. The tyrosine supplement was provided to participants at two 
separate occasions, the first 10 g was administered 15 minutes prior to the beginning of exercise 
while a further 10 g was provided after 60 minutes of exercise. Exercise capacity was 
significantly reduced when participants were administered paroxetine; there were no significant 
differences in time to exhaustion between the tyrosine trial, the branched chain amino acid trial 
or the placebo. It is possible that the exercise protocol was not physiologically or psychologically 
demanding enough to elicit a response from the tyrosine dose. This may have been caused by 
feedback inhibition of tyrosine hydroxylase in response to increased tyrosine availability in the 
brain. Had the exercise protocol been of a greater intensity or been carried out in a more stressful 
environment, the effects of tyrosine may have been more pronounced due to increased neuronal 
firing rates and a greater demand for tyrosine availability (Fernstrom, 1983; Brady et al., 1980; 
Melamed et al.,1980).   
 
A study by Chinevere, Sawyer, Creer, Conlee and Parcell (2002) examined the effect of 
supplementing tyrosine alone, or in combination with carbohydrate, on endurance exercise 
performance in temperate environmental conditions. Nine competitive cyclists cycled for 90 
minutes at 70% of their peak oxygen uptake which was immediately followed by a simulated 
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time trial. This protocol was conducted under four different feeding conditions which were 
randomly assigned to the participants, and included 5 mL·kg body mass -1 of water (placebo), a 5 
mL·kg body mass -1 solution of polydextrose (carbohydrate), a 5 mL·kg body mass-1 solution of 
tyrosine or a 5 mL·kg body mass -1 solution with polydextrose and tyrosine (carbohydrate + 
tyrosine). No significant differences were found in time trial performance between the 
conditions, nor in subjective ratings, or physiological measures. Despite being unable to find any 
statistical differences in time trial performance; the results demonstrated that tyrosine did appear 
to influence the results of the study somewhat. Out of the nine participants taking part, six 
completed the time trial faster when supplemented with tyrosine compared to placebo. 
Furthermore, when participant were provided with a combination of tyrosine and carbohydrate, 
six out of nine participants completed the time trial faster compared to the other trials while eight 
out of the nine participants completed the time trial faster when provided with a combination 
tyrosine and carbohydrate compared to tyrosine or placebo alone. The study also found that 
ratings of perceived exertion were lower when participants were provided with the sole tyrosine 
solution. It is possible that, if the time trial had been longer or completed in the heat thus making 
it more demanding, the results may have shown a significant effect of tyrosine on time trial 
performance. 
  
Sutton, Coll and Deuster (2005) examined how tyrosine ingestion affects endurance, muscle 
strength and anaerobic performance. Twenty men, all of whom were combat trained soldiers, 
completed two load carriage sessions to exhaustion on a treadmill following supplementation of 
either 150 mg·kg body mass-1 tyrosine in 70 g of apple sauce or placebo. Following completion 
of the load carriage test, a physical performance battery was administered which included stair 
stepping (with weight), maximal and sub maximal handgrips and pull ups to exhaustion. On 
completion of the trials it was found that tyrosine supplementation had not significantly 
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improved treadmill performance time nor muscle strength and anaerobic performance. The study 
did find there to be a large increase in plasma tyrosine following tyrosine supplementation 
although the use of apple sauce in the process of supplementing the tyrosine may have affected 
the results due to the effect of carbohydrate (present in the apple sauce) on plasma amino acid 
ratios (Fernstrom and Wurtman, 1971).   
 
Tumilty, Davison, Beckmann and Thatcher (2011) used eight males in their study to examine the 
effect of tyrosine supplementation on exercise capacity in the heat. Two exercise trials were 
performed by the participants in a randomised fashion, 1 hour after consuming a 500 mL drink 
containing either 150 mg·kg body mass-1 tyrosine or a 500 mL placebo drink containing no 
tyrosine.  Participants cycled to exhaustion at an exercise intensity of 68 ± 5 V̇O2peak in a 
temperature of 30˚C and 60% relative humidity. Tyrosine supplementation resulted in a 2.9 fold 
increase in the plasma ratio of tyrosine: competing amino acids which was not observed in the 
placebo trial. It was found that participants exercised for 15 ± 11% longer with tyrosine 
compared with placebo despite values for core temperature, skin temperature, heart rate, ratings 
of perceived exertion and thermal sensation all being similar. The study was the first to 
demonstrate that acute tyrosine administration was associated with an increased capacity to 
endure exercise in the heat. 
 
However, Watson, Enever, Page, Stockwell and Maughan (2012) also examined whether tyrosine 
supplementation affects exercise capacity in a warm environment, using a similar exercise 
protocol to the Tumilty et al., (2011) study. Sixty minutes prior to exercise, participants 
consumed a 250 mL aliquot of tyrosine or placebo and then an identical 250 mL aliquot, 30 
minutes prior to exercise, before cycling to exhaustion at 70% V̇O2 max. Participants also 
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consumed either tyrosine or placebo after every 10 minutes of exercise had elapsed. The total 
amount of tyrosine consumed in the tyrosine trial was 150 mg·kg body mass-1. The study 
measured participant’s cognitive function, using the Stroop word and colour test, Sternberg’s 
memory scanning task and a rapid visual information processing task (Watson et al., 2012). 
Cognitive function was measured before drink ingestion, immediately before exercise 
commenced and at exhaustion. Tyrosine supplementation had no effect on exercise capacity. The 
study did find that exercise caused an increase in error rate during the Stroop test but this was not 
influenced by the tyrosine supplement.  
 
Other work by Tumilty, Davison, Beckmann and Thatcher (2013) explored the possibility of 
whether reduced plasma tyrosine and phenylalanine is associated with a reduced exercise 
capacity in the heat.  The study again used eight male participants who completed two trials, 
consuming either 500 ml of sugar-free flavoured water containing either a balanced amino acid 
mixture containing 9 amino acids (isoleucine 15 g, leucine 22.5 g, valine 17.5 g, lysine17.5 g, 
methionine 5 g, threonine 10 g,  tryptophan 2.5 g,  12.5 g tyrosine and 12.5 g of phenylalanine) 
or the same mixture minus tyrosine and phenylalanine, designed to lower the blood ratio of 
plasma tyrosine and phenylalanine: competing amino acids.  Subjects were required to cycle until 
exhaustion at 63 ± 5 % V̇O2 peak within a temperature of 30˚C and 60% relative humidity. The 
study’s results demonstrated that exercise time was shorter in the tyrosine-free trial compared to 
the balanced mixture trial. This study provided further evidence that the availability of tyrosine 
within the bloodstream can influence the ability to carry out prolonged, submaximal intensity 
exercise in the heat. 
 
More recent work, published by Tumilty et al., (2014) examined whether self-paced exercise 
performance in the heat is enhanced with tyrosine. Due to the nature of a self-paced time trial, 
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which is highly influenced by arousal and motivation, it was hypothesised that this would 
provide the necessary environment to highlight any apparent effects of tyrosine supplementation 
compared to a constant load capacity trial (Tumilty et al., 2014). This study recruited 7 
endurance trained males to perform two experimental trials in the heat (30˚C and 60% relative 
humidity). Over the two trials, subjects consumed either 150 mg·kg body mass-1 of tyrosine or a 
placebo in a randomised, crossover design. Following 60 minutes of rest after supplement or 
placebo administration, participants cycled for 60 minutes at 57 ± 4% peak oxygen uptake before 
completing a time trial which required completion of an individualised work target quantity as 
quickly as possible. The study found that tyrosine supplementation increased the ratio of plasma 
tyrosine to other amino acids competing for uptake at the blood brain barrier 2.5-fold but found 
no change in the placebo trial. Power output throughout the time trial and performance were not 
improved following tyrosine administration.   Thermal sensation, ratings of perceived exertion, 
core temperature, skin temperature and heart rate were similar between the two experimental 
conditions which indicated that ingestion of tyrosine did not influence the physiological response 
to self-paced exercise in the heat. The failure to find any significant effect of tyrosine on exercise 
performance led the authors to suggest that one possible reason why tyrosine was not effective 
may have been because tyrosine, as a general catecholamine precursor, could have augmented 
central noradrenaline activity (Tumilty et al., 2014). Increased noradrenaline activity is 
associated with reduced exercise performance and is evident in the previously discussed study by 
Roelands et al., (2008). Tumilty et al., (2014) also suggests that the adoption of a range of 
tyrosine doses may identify whether or not a larger tyrosine dose has the ability to improve 
exercise performance in the heat. 
 
One study which has used two different doses was published by Coull, Chrismas, Watson, 
Horsfall and Taylor (2015). This study examined the effect of 150 and 300 mg·kg body mass-1 
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doses of tyrosine on blood concentrations.  However, they only used the dose which increased 
blood tyrosine to the largest extent to examine its effect on cognitive and physical performance in 
the heat in a follow-up study. Therefore, it is still unclear what effect different doses of tyrosine 
may have on exercise in the heat.  The exercise protocol, which included a 60 minute walk at 6.5 
km·h-1 followed by a 2.4 km time trial with a 25 kg backpack, was completed at 40˚C and 30% 
relative humidity with cognitive function test before, during and after exercise. The study found 
tyrosine to have no significant effect on physical or cognitive performance despite a significant 
rise in serum tyrosine: competing amino acids. 
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Table 2. Summary of studies examining the effects of tyrosine supplementation on exercise, physiological responses and cognitive performance in 
vivo 
Animal Studies 
Study Animal Treatment Protocol Main findings 
Acworth et al., 
(1988) 
Male Sprague-Dawley rats 50-200 mg·kg-1 tyrosine.  Direct brain microdialysis  Dose related increase in 
extracellular dopamine.  
Badaway and 
Williams (1982) 
Male wistar rats  5 mg·kg-1 tyrosine to 
500 mg·kg-1 tyrosine. 
In vivo examination Catecholamine synthesis enhanced 
in small tyrosine doses but 
ineffective at > 50 mg·kg. 
Brady et al., 
(1980) 
Male CF-1 mice Tyrosine or Casein diet. Cold water swim at 2˚C - 
6˚C 
Increased aggressive behaviour in 
young mice. Tyrosine prevented 
decreases in locomotion in stressed 
and non-stressed older mice. 
Tyrosine administration increased 




Choi et al., 
(2013) 
Male Sprague-Dawley rats  BCAA / BCAA + 
Tyrosine. 
Sedentary and Exercising 
rats provided treatment. 
Sacrificed 60 minutes after 
treatment ingestion. 
BCAA reduced brain tryptophan and 
tyrosine concentrations. Lowered 
serotonin and catecholamine synthesis.  
Reductions in tyrosine concentration 
and catecholamine synthesis following 
BCAA intake can be reduced with co 
administering tyrosine. 
During et al., 
(1988) 
Sprague-Dawley rats 50–100 mg·kg body mass-
1 Tyrosine.  
Partial lesioning of 
nigrostriatal neurons. 
Increased brain dopamine 
concentration with tyrosine. Lesioning 
of nigrostriatal neurons increased effect 
of tyrosine on dopamine release in 
surviving neurons. 
Lehnert et al., 
(1984) 
Sprague-Dawley rats Tyrosine or tyrosine + 
valine or control. 
Tail shock + locomotion 
and exploration task. 
Tyrosine maintained brain 






Lieberman et al., 
(2005) 
98 Fischer rats  400 mg·kg body mass-1 
tyrosine. 
Heat exposure at 41ºC 
with coping and memory 
tasks.  
Increased coping behaviour and 
maintained brain noradrenaline 
release with tyrosine. 
Neri et al., (1995) 20 males 150 mg·kg body mass-1 
tyrosine or placebo. 
Sleep loss + cognitive 
performance tasks. 
Tyrosine prevented performance 
decrements.  
Shurtleff et al., 
(1993) 
8 Long Evans rats 50, 100, 200 mg·kg-1 
tyrosine. 
Delayed matching to 
sample task at 2˚C and 
22˚C. 
Tyrosine partially improved DMTS 





Male Fischer rats Tyrosine (alone), 
amphetamine or 
phenylpropanolamine 
alone or with tyrosine (200 
or 400 mg·kg body mass-
1). 
Cold immersion and 
forced swim test.  
Tyrosine increased brain 
norepinephrine concentration. All 
treatments improved performance. 
Performance further enhanced with 






Study Population Treatment Protocol Main findings 
Banderet and 
Lieberman (1984) 
23 males  100 mg·kg body mass-1 
tyrosine. 
4.5 cold and hypoxia 
exposure.  
Tyrosine improved adverse mood 
and cognitive function in subjects 
most affected by environment. 
Chinevere et al., 
(2002) 
9 competitive cyclists  25 mg·kg body weight-1 
tyrosine or 25 mg·kg body 
mass-1 tyrosine with 70 g·l-
1 polydextrose. 
Cycling at 70% V̇O2peak for 
90 minutes followed by a 
time trial.  
Tyrosine had no effect on time trial 
performance following 90 minutes 
of submaximal exercise. 
Coull et al., 
(2014) 
8 male soccer players 150 mg·kg body mass-1 
tyrosine.  
Individualised 90 minute 
soccer simulation 
intermittent soccer 
performance test at 25˚C. 
Tyrosine associated with improved 
vigilance and mental effort. 
Tyrosine may improve cognitive 






Coull et al., 
(2015) 
21 males 2 doses of 150 mg·kg 
body mass-1 tyrosine or 2 
doses 75 mg·kg body 
mass-1 tyrosine. 
Military based load carriage 
protocol including 60 minute 
walk followed by 2.4 km 
time trial with 25 kg 
backpack at 40˚C. 
Single dose of 150 mg·kg body 
mass-1 tyrosine as efficient at 
elevating serum tyrosine 
concentration as double dose. No 
effect of tyrosine in alleviating 
impaired cognitive function. 
 
Deijen et al., 
(1998) 
21 military cadets 5 x doses of 2 g tyrosine. Cognitive tasks including 
a memory comparison 
task, tracking task, 
continuous memory task, 
double task. 
Tyrosine may improve cognitive 
task performance by reducing stress 









Lieberman et al., 
(2014)  
78 male and female 
military personnel  
2 x 150 mg·kg body mass-
1 tyrosine. 
2 mock interrogations 
during several days of 
simulated captivity at 
SERE school. Mood, 
cortisol and heart rate 
measured. 
Tyrosine increased ratings of anger 
during simulated captivity. 
Mahoney et al., 
(2007) 
19 male and female 
volunteers 
2 x 150 mg·kg-1 tyrosine.  2 x 90 minute cold water 
immersions to induce a 
decrease in core 
temperature. Cognitive 
performance, mood and 
salivary cortisol analysed.  
Tyrosine resulted in improved 
match to sample memory measure 
and improved response time 











22 healthy adults 2 g tyrosine dissolved in 
400 ml orange juice 
administered in 2 separate 
doses.  
Participants rated mood on 
a 9 x 9 pleasure x arousal 
grid before administration 
of tyrosine. Mood was 
rated again following 
tyrosine administration 
before completing the task 
switching paradigm. Mood 
was then rated for a third 
time.  
Tyrosine promotes cognitive 
flexibility. Tyrosine facilitates 
cognitive flexibility by repleting 
cognitive resources. 
Strüder et al., 
(1998)  
10 males  21 g BCAA, 20 g tyrosine, 
20 mg paroxetine.  
Cycling time to 
exhaustion.  
BCAAs and tyrosine had no effect 
on time to exhaustion. Time to 
exhaustion was lower with 





Sutton et al., 
(2005) 
20 males 150 mg·kg body mass-1 
tyrosine administered in 
apple sauce. 
2 load carriage sessions 
followed by a physical 
performance battery. 
Including maximal and 
submaximal handgrip, 
pull-ups, and stair stepping 




Total time on treadmill was 
unaffected by tyrosine ingestion. 
Physical performance battery was 
also unaffected by tyrosine. 
Tumilty et al., 
(2011) 
8 healthy males  150 mg·kg body mass-1 
tyrosine. 
Cycling to exhaustion at 
68 ± 5 % V̇O2peak at 30˚C. 
Time to exhaustion increased with 
tyrosine despite similar values for 
core temperature, heart rate, thermal 





Tumilty et al., 
(2014) 
7 endurance trained males 150 mg·kg body mass-1 
tyrosine. 
60 minute cycling at 57 ± 
4 V̇O2peak followed by a 
cycling time trial. 
Tyrosine had no effect on cycling 
performance in comparison to 
placebo despite marked rises in 
plasma tyrosine. 
 
Watson et al., 
(2012) 
8 males  150 mg·kg body mass-1 
tyrosine. 
Cycling to exhaustion at 
70% V̇O2peak with 
cognitive function tests at 
before drink ingestion, at 
the end of 1 hour rest 
period and at exhaustion.  
Tyrosine did not influence time to 
exhaustion despite increase in 
serum tyrosine and had no effect on 
cognitive function.  
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There are no published studies which have examined the effect of varying doses of tyrosine in 
humans, before prolonged exercise in the heat. Coull et al., (2015) initially used a high and low 
dose in the primary stages of their study in order to identify an optimal dose for increasing serum 
tyrosine but did not systematically examine the effect of both doses on exercise and cognitive 
function. Many studies, such as Sutton et al., (2005), Tumilty et al., (2011), Watson et al., 
(2012), Tumilty et al., (2014) and Coull et al., (2014) have all favoured a dose of 150 mg·kg 
body mass-1 in their studies. These studies report large increases in the blood ratio of tyrosine: 
LNAA but the conflicting results with the adoption of this dose could suggest that this is 
insufficient to maintain brain tyrosine concentrations in all individuals, under the physiologically 
demanding conditions of exercise and heat. Previous studies which have adopted a higher dose 
than 150 mg·kg body mass-1, such as Mahoney et al., (2007; 300 mg·kg body mass
-1), reported 
improved cognitive function during exposure to cold stress.  Therefore, it is prudent to 
investigate whether the acute dose of tyrosine administered may influence exercise performance 
in the heat. Administering higher doses of tyrosine may maximise the increase in the blood ratio 
of tyrosine: LNAA, favouring entry of tyrosine into the brain. Maximising brain tyrosine should, 
in theory, result in an increase in the synthesis of dopamine in the brain assuming that exercise 
combined with heat stress, is sufficiently demanding to stress brain catecholamine function.  
Previous studies have shown that tolerance to exercise in the heat can be predicted by 
dopaminergic activity within the hypothalamus (Bridge et al., 2003), providing some support for 
this. Increases in neuronal firing will result in a decrease in precursor availability and so 
additional tyrosine should maintain catecholamine synthesis and release (Fernstrom, 1983).  The 
additional tyrosine should, in theory, maintain brain catecholamine activity and subsequently 
maintain, or improve performance during exercise in the heat. 
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Aims and Hypothesis  
The present study aims to assess the effect of a low, medium or high dose of tyrosine on exercise 
performance in the heat. It is hypothesised that tyrosine will improve performance in the medium 
and high dose as these should increase the ratio of tyrosine: LNAA to a greater extent compared 
to the low dose. The low dose to be used in the present study has produced mixed results to date 
and therefore it is plausible to suggest that the medium and high dose of tyrosine will increase the 
ratio of tyrosine: LNAA to a greater extent. Therefore, this will provide greater precursor 
availability for catecholamine synthesis under conditions of increased neuronal firing. This may 

















All participants volunteered to take part and were given written information on the purpose and 
procedures of the study before giving verbal and written informed consent to proceed. 
Participants completed a health questionnaire prior to commencing the study in order to identify 
any reason that would preclude involvement. Nine healthy males, all of whom exercised 
regularly, volunteered to participate. None of the participants were specifically acclimated to 
exercise in the heat. One participant withdrew from the study having completed two laboratory 
visits and the remaining eight participants completed all testing. Data for eight participants were 
used for statistical analysis. The physical characteristics of these participants were: mean age, 23 
± 4 (SD) years; height, 181 ± 7 cm; body mass, 76.1 ± 5.9 kg; peak oxygen uptake (V̇O2 peak) 
obtained from ramp incremental test, 4.1 ± 0.5 L·min-1; peak power achieved during ramp test, 
327 ± 44 W.   
 
Ethical approval for the study was granted by Aberystwyth University Research Ethics 
Committee prior to any subject recruitment or testing procedures taking place. All the 
participants who took part were informed that participation was voluntary and they were free to 
withdraw from the study at any point without giving prior notice.  
 
Experimental Protocol  
Participants attended the laboratory on six separate occasions in the morning, having refrained 
from the consumption of alcohol and any strenuous or unaccustomed physical activity for 24 
prior to each visit. They were asked to arrive at the lab well rested, and to sleep for a minimum of 
8 hours the night before each visit.  Verbal adherence to this was given on each visit.  
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Furthermore, participants recorded their diet for 24 hours prior to the familiarisation and repeated 
their dietary intake before each subsequent experimental visit.  Participants attended each trial 
after an overnight fast of at least 8 hours (not including the V̇O2peak test, see below) but were 
instructed to consume 500 mL of plain tap water, 2 hours before arriving at the lab for each visit. 
The first visit required participants to complete a ramp incremental exercise test on a cycle 
ergometer (Lode Excalibur Sport 2, Groningen, Netherlands)  to measure V̇O2peak, using an 
online breath by breath system (Quark PFT, Cosmed, Rome, Italy). At least 48 hours later, 
participants completed a familiarization visit to become accustomed to the experimental 
procedures, including exercising in the heat, and to minimise any learning effects. The 
familiarisation trial was identical to the placebo trial, and included administration of the placebo 
drink (see below) but no blood sampling was performed. Finally, each participant completed the 
remaining four trials in a randomised, crossover fashion, with at least 7 days between each visit. 
Trial order was randomised using an open source software package (PEPI for Windows, Brixton 
Health). In three of the trials participants consumed tyrosine in one of the three experimental 
doses (Low, Medium or High) and in the fourth trial the placebo drink was administered. 
Administration of the experimental and placebo drinks was double-blinded and all drinks were 
prepared by a separate drink manager, not directly involved in data collection. 
 
The tyrosine drinks (SHS International, UK) provided a total of 150 (Low), 300 (Medium) or 
400 (High) mg·kg body mass-1 tyrosine. All drinks were administered in two separate bottles 
which were consumed an hour apart. The 300 mg·kg dose was administered as two bottles each 
containing 300 mL sugar-free flavoured squash (Morrisons, Bradford, UK) and tap water and 
150 mg·kg body mass-1 tyrosine whereas the 400 mg·kg dose was administered as two bottles 
each containing 300 mL sugar-free lemon and lime flavoured squash and tap water and 200 
mg·kg body mass of tyrosine. The 150 mg·kg dose was administered as two bottles, the first 
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containing 300 mL sugar-free flavoured squash and tap water and 150 mg·kg body mass of 
tyrosine and the second bottle containing the same fluid but no tyrosine. The placebo dose was 
administered in two bottles and contained the same fluid volume and constituents as the 
experimental drinks but no tyrosine.    
 
Maximal Oxygen Uptake Test  
All participants completed a 30 W·min-1 ramp test to exhaustion on a cycle ergometer to establish 
their V̇O2peak. Prior to each peak oxygen uptake test, the breath-by-breath analyser  was 
calibrated using a standard 3 L volume cylinder (Hans Rudolf, Kansas, USA) and gases of 
known concentration, assuming accuracy of the concentration certificates provided by the 
supplier (BOC, Guildford, UK). Participant’s height (Holtain Ltd, Crymych, UK) and nude body 
mass (Seca 899, Hamburg, Germany) were recorded before being fitted with a radiotelemetry 
heart rate monitor (Polar, FS2C, Kempele, Finland). Once seated on the cycle ergometer seat 
height and handle bar position was adjusted into the appropriate position for each participant and 
recorded for replication in subsequent visits. Participants were fitted with a sterilised silicon face 
mask (Hans Rudolf, Kansas, USA), which was held in place via a head cap (Hans Rudolf, 
Kansas, USA), and sat quietly on the ergometer for one minute to regulate their breathing. The 
first three minutes of exercise were unloaded (0 W) then the power output increased by 1 W 
every 2 seconds until participants reached volitional exhaustion. No information relating to 
performance was visible to the participant and strong verbal encouragement was provided 
throughout. 
 
Following completion of the V̇O2 peak test, the data was averaged over six seconds and was 
exported to Microsoft Excel (Microsoft Excel 2010, Computer Software, USA). Each 
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participant’s gas exchange threshold (defined as an increase in the rate at which V CO2 rises 
versus  V O2, accompanied by an increase in V E/ V O2 while V E/ V CO2 continued to decrease or 
levelled off) was determined through the use of modified version of the v-slope method (Beaver 
et al., 1985). Data for V̇O2 and V̇CO2 were plotted against time in order for the gas exchange 
threshold to be visually identified and were confirmed by a graph of ventilatory equivalents 
versus time. Identification of the gas exchange threshold for each subject was confirmed by an 
additional, separate researcher. The power output equivalent to 10% ∆ (Power output equivalent 
to 10% of the difference between the V̇O2 at the gas exchange threshold and the V̇O2peak) was 
calculated individually for each subject from the gas exchange data and adopted for the constant-
load, submaximal portion of the exercise protocol (described below).   
 
Experimental Trials  
All familiarisation and experimental trials commenced between 0700 and 0800 hours and at the 
same time of day for each participant, across trials. Subjects were required to fully empty their 
bladder into a 1 L Pyrex beaker (Fisher Scientific UK Ltd., Loughborough, UK) and provide 
their nude body mass. Urine volume was determined using a 500 mL measuring cylinder (Fisher 
Scientific UK Ltd., Loughborough, UK) before urine osmolality was measured, on arrival at the 
lab for each visit, via a digital refractometer  (Pocket  Osmocheck 4595, Vitech  Scientific, West 
Sussex, UK), to ensure participants were not hypohydrated (urine osmolality > 700 milliosmoles 
per kg; ACSM, 2007). If it was found that participants were hypohydrated, testing was 
rescheduled by a minimum of 24 hours to the next available day convenient for the participant 
and investigator. Participants were instructed to drink fluids regularly to ensure rehydration prior 
to returning to the lab for any rescheduled visits. Approximately 1 ml of urine was immediately 
frozen for subsequent measurement via freezing point depression and this data is reported below 
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(Osmostat 030, Gonotec, Berlin). The analyser was calibrated using calibration fluids of known 
osmolality (0, 300, and 850 mosmol·kg-1).  Participants were asked to fit a rectal thermistor 
(Grant Instruments, Cambridge, England, UK) 10cm beyond the anal sphincter, in a private 
room, as well as fit a heart rate telemetry band (Polar S610i, Polar Electro Oy, Tampere, Finland)  
on the chest. Skin thermistors (Grant Instruments, Cambridge, England) were attached to the 
participant’s right calf, halfway between the ankle and the knee; to the right anterior thigh, 
halfway between the knee and hip; right upper section of chest, midway between the nipple line 
and the clavicle; and on the right arm, midway between the shoulder and the elbow, over the 
tricep. The surface skin probes were securely attached to the skin at the thermistor head using 
breathable adhesive medical tape (Hypafix, Bsn Medical, Hull, UK) and then connected to a data 
logger (Squirrel SQ2020, Grant Instruments, Cambridge, England). The recorded values for skin 
temperature were used to calculate mean weighted skin temperature using the equation devised 
by Ramanathan (1964): 
 
                                      0.3·(Tchest + Tarm) + 0.2·(Tthigh + Tleg)    [equation 1] 
 
where Tchest is temperature at the chest site, Tarm is temperature at the arm site, Tthigh is 
temperature at the thigh site and Tleg is temperature at the calf site.  
 
Participants sat quietly for a minimum of 15 minutes prior to a 6 mL blood sample (Rest) being 
obtained from the antecubital vein and collected into a heparinised vacutainer (BD Vacutainer 
Systems, Plymouth, UK), with minimal stasis, using standard venepuncture methods. Following 
drink ingestion, participants sat quietly in the laboratory for one hour. During this period, core, 
thigh, calf, chest and arm temperature, heart rate, air temperature and humidity were all recorded 
every 5 minutes (Squirrel SQ2020, Grant Instruments, Cambridge, England). Thermal sensation 
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was also recorded every 5 minutes, using a validated scale ranging from -10 ‘Cold impossible to 
bear’ to +10 ‘Hot impossible to bear’ (adapted from Parsons, 2003). After 60 minutes, a second 
blood sample was obtained (Pre) using exactly the same procedure described above, and then 
participants drank a second 300 mL of sugar-free squash and tap water containing  tyrosine or the 
placebo. Drinks were provided to the participant in an opaque plastic bottle and shaken well 
before consumption to mask any differences in taste, texture and colour. Prior pilot work 
conducted with two volunteers, who did not participate in the study, confirmed that the drinks 
were indistinguishable in texture and taste.  
 
Participants entered the climate chamber (Design Environmental, Gwent, Wales), which was 
maintained at a temperature of 30˚C and 60% relative humidity [mean wind speed within 
chamber was 0.6 mph, measured using a hand-held anemometer (Kestrel 1000, Richard Paul 
Russell Ltd, Lymington, UK)], and positioned themselves on the cycle ergometer (Lode 
Excalibur Sport 2, Groningen, Netherlands). Immediately before exercise commenced, baseline 
measures were taken for core and skin temperature, heart rate and thermal sensation. Air 
temperature and humidity were also recorded to the nearest 0.1˚C and 0.1% respectively, by the 
chamber control software and wind speed was monitored within the chamber using the hand-held 
anemometer. Measurement of wind speed was calculated as the mean of four measurements 
taken at head height in front, behind, to the left and to the right of each participant as they were 
seated on the cycle ergometer. Participants began cycling, with no prior warm up, at a constant 
intensity equivalent to 10% Δ for 60 minutes (129 ± 17 W and 47.8 ± 6.02 % V̇O2  peak in this 
group). The purpose of the 60 minute exercise period was to induce hyperthermia prior to the 
start of the time trial. Participants were given no feedback on time elapsed. Core and skin 
temperature, heart rate, thermal sensation, ratings of perceived exertion (Borg, 1982), air 
temperature, humidity and wind speed were recorded after every 5 minutes of exercise and in the 
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last few seconds of the 60 minute exercise period. Drinks were provided to the participants (2 
mL·kg body mass-1 tap water with 20% sugar free lemon and lime squash) after 15, 30, 45 and 59 
minutes of exercise had elapsed. Following completion of the 60 minute exercise period, 
participants dismounted the cycle ergometer and were quickly moved to a chair, which was 
positioned inside the heat chamber directly adjacent to the bike, where  a third venous blood 
sample was obtained (Post 60). Acquisition of the Post 60 blood sample occurred within two 
minutes in all cases. Participants remounted the cycle ergometer and performed a simulated 
cycling time trial. The time trial in the present study has been used previously in our lab (Tumilty 
et al., 2014) and is based on an original validated time trial protocol by Jeukendrup et al., (1996). 
The time trial required participants to complete a quantity of work (326 ± 37 kJ in this group) as 
quickly as possible, equivalent to 30 minutes of cycle exercise at 60% of the power output which 
elicited V̇O2 peak during the initial ramp test. Work target quantities were calculated prior to 
familiarisation and experimental time trials.  During the time trial, the cycle ergometer was set in 
linear mode so that power output, and work accumulated, was related directly to pedalling 
cadence. The linear factor for each participant was calculated using the equation: 
 
 
       LF =
0.6·PO at V̇O2peak   
RPM2
    [Equation 2] 
where LF is Linear Factor, PO at V̇O2 peak is the power output (W) which elicited VO2 peak during 





The preferred cadence at 60% V̇O2 peak for each participant, which was used in subsequent 
linear factor calculations, was identified during the familiarisation trial.  Between 48 and 50 
minutes of the 60 minute cycling period, participants were instructed to maintain their preferred 
cadence as the power output was increased to each individual’s 60% peak ramp power value.  
 
Before commencing, participants were instructed to complete the time trial as quickly as possible 
but no further motivational encouragement was provided. Participants could view total work 
accumulated from the bike console, which was positioned on the frame of the bike and in view of 
the participant.  No feedback was provided on power output, time elapsed or pedalling cadence. 
Information on cumulative work targets was visible on a laminated card positioned on the bike 
handlebars, and displayed the target work required to complete 25%, 50%, 75% and 100% of the 
individualised work target. Participants were permitted to drink ad libitum during the time trial 
(tap water with 20% sugar free lemon lime squash) and the volume of fluid consumed was 
recorded during each trial.  Following the completion of the time trial, participants were quickly 
moved back to the adjacent chair within the chamber and a final blood sample was taken (PTT), 
within a maximum of two minutes. Participants were immediately removed from the climate 
chamber and sat in a cool environment for 15 minutes to recover. During this period, core and 
skin temperature, heart rate, thermal sensation, air temperature and humidity were recorded every 
5 minutes. Once complete, the skin thermistors were removed and the rectal thermistor was 
removed by the participant in private, before emptying their bladder so post exercise urine 
volume and osmolality could be recorded. A further 1 ml of urine was frozen for osmolality 
measurement using freezing point depression. Finally, nude body mass was recorded a second 
time.  Changes in participant’s body mass which occurred during exercise were calculated as the 
difference between pre exercise and post exercise weight, accounting for fluid consumption and 





Blood Treatment  
A 1 mL aliquot of whole blood was transferred from the heparinised vacutainer into a 1.5 mL 
eppendorf. Blood glucose and blood lactate were analysed using an automated glucose/lactate 
analyser (2300 Stat Plus, Yellow Spring Instrument Co., Ohio, USA).  The analyser was 
calibrated regularly with standard concentrations for glucose (0.00, and 50.00 mmol·L-1) and 
lactate (0.00 and 30.00 mmol·L-1). The coefficient of variation for 10 repeated measurements on 
a sample standard of known concentration for blood glucose (6.14 mmol·L-1) and blood lactate 
(5.35 mmol·L-1) were 1.7% and 1.5%, respectively (Tumilty, 2011).  The remaining whole blood 
was centrifuged at 1500 g for 10 minutes at 4˚C. The separated plasma was pipetted evenly into 
two separate eppendorfs and frozen at -80˚C for subsequent analysis of amino acids using gas 
chromatography mass spectrometry (GC-MS).  Haemoglobin concentration was measured using 
an automated haematology analyser (ABX Pentra 60C+, Horiba ABX Diagnostics, Northampton, 
UK). This method of analysis has a coefficient of variation of 0.3%, for 10 repeated 
measurements on the same sample standard (Tumilty, 2011).  Haematocrit was measured using 
standard microcentrifugation. Whole blood from the 1 mL taken from the vacutainer was drawn 
into three separate glass capillary tubes and spun for 5 minutes at 14000 g using a micro-
centrifuge (Haematospin 1400, Hawksley, Lancing, UK). Individual tubes were then placed into 
a Hawksley micro-haematocrit reader (Hawksley, Lancing, UK) and red blood cell mass was 
recorded. This technique had a coefficient of variation of 0.8% for ten repeated measurements on 
the same sample (Tumilty, 2011).  Measurements of blood glucose, blood lactate and 





Amino Acid Analysis 
Amino acid analysis was completed by a separate investigator with the methods used identical to 
previous studies of similar design (Tumilty, 2011) to the present investigation. GC-MS was used 
to measure plasma amino acids concentrations in heparinised plasma. From ice, 200 μL of 
defrosted plasma samples were transferred into ~500 μL micro tubes which contained glass 
beads (2 mL Eppendorf), diluted with 1520 μL degassed (He) and chilled (-20°C) 
methanol/chloroform (4:1, v/v), vortexed for 10 seconds, shaken for 15 minutes at 4°C and then 
centrifuged for 5 minutes at 4°C and 18000 g (Hettich EBA 12R, Tuttlingen, Germany; Tumilty, 
2011).  For GC-MS analysis, 420 μL of the supernatant was transferred into separate 2 mL micro 
tubes and dried in vacuo (speed vac, Univapo 150 H). The sample tubes containing supernatant 
were then stored at -80°C (Tumilty, 2011).  Two-step derivatization of dried samples was 
achieved by protecting the carbonyl moieties by methoximation using 60 μL of a 20 mg·mL-1 
solution of methoxyamine hydrochloride (Fluka) in pyridine (Fluka) at 30°C for 90 minutes 
(Tumilty, 2011).  Acidic protons were then derivatized with 60μL N-methyl-N-
trimethylsilyltrifluoride (MSTFA, M&N) at 37°C for 30 minutes. Sixty μL were transferred into 
200 μL glass vials (Chromacol) and 1 μL were injected split-less into a Leco Pegasus III GC-tof-
MS system (St. Joseph, USA) consisting of a Focus autosampler (Anatune), an Agilent 6890 N 
gas chromatograph equipped with a DB5-MS column (20 m x 0.25 mm ID x 0.25 μm film; 
Tumilty, 2011).  Injector temperature was 250°C with the transfer line set to 260°C and the ion 
source temperature held at 230°C.  Helium flow was 1.2 mL·min-1.  Following 1 minute at 80°C, 
oven temperature was increased by 30°C min-1 to 330°C, maintained at 330°C for 3 minutes and 
then decreased to 80°C (Tumilty, 2011). Automated deconvolution and peak finding was 
completed using ChromaTof software (Leco, St. Joseph, USA).  Through use of this technique, 
the coefficient of variation for the measurement of individual amino acids was: leucine, 8.5%; 
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isoleucine, 9.7%; valine, 5.8%; methionine, 11.4%; tryptophan, 5.2%; phenylalanine, 7.5% and 
tyrosine, 6.5% (Tumilty, 2011).  
 
Statistical Analysis 
A computerized statistical package was used to analyse all data (SPSS version 17.0, SPSS inc., 
Chicago, IL). Normally distributed data are presented as mean ± SD. Normally distributed data 
throughout the trials were compared using 2-way (time x trial) repeated measures ANOVA. 
Follow up post hoc tests were used, where appropriate, using Student’s paired T-tests with the 
Bonferroni correction.   Non-normally distributed data were analysed using Friedmans Test and 
are presented as median (range). Where necessary, post hoc tests were carried out using 
Wilcoxon signed rank tests with the Bonferroni correction. Statistical significance was accepted 


















Time trial performance  
 
After completing all trials, three participants successfully guessed the trial in which they received 
the placebo, stating differences in the drinks texture, although were unable to distinguish between 
the different doses of tyrosine. The remaining five participants were unable to distinguish 
between the tyrosine doses or placebo.  This indicates successful drinks blinding. Tyrosine did 
not influence the time taken to complete the time trial (P = 0.588; 34.2 ± 2.5 min in PLA, 35.4 ± 
5.9 min in LOW, 35.2 ± 5.2 min in MED and 36.4 ± 5.9 min in  HIGH; Figure 1A). There were 
no significant differences in median power output between conditions at any point during the 














Figure 1. Mean  (± SD) time to complete time trial (A) and median (range) power output 
(B) up until 25 mins of time trial had elapsed (last common time-point when all participants 
were still exercising) and at end of exercise, in the placebo trial (PLA), 150 mg·kg (LOW), 
300 mg·kg (MED) and 400 mg·kg (HIGH) tyrosine trials. (n = 8). * Significant difference in 




































































Blood Analysis  
For clarity, caps on error bars have been removed in all the time-series graphs.  All blood 
measures were adjusted for plasma volume changes. The plasma ratio of tyrosine: ∑LNAA (sum 
of the plasma concentration of tryptophan, valine, leucine, isoleucine, phenylalanine and 
methionine) was similar at rest between all trials (P = 0.657) but increased significantly from rest 
in all tyrosine conditions (P < 0.01; Figure 2). The tyrosine ratio at P60 was similar between 
LOW and MED (P = 0.107), LOW and HIGH (P = 0.070) and MED and HIGH (P = 0.552) but 
was significantly higher in MED and HIGH at PTT compared to LOW and PLA (P < 0.05). 
There was no difference between MED and HIGH at PTT (P = 0.641).  The tyrosine ratio 
remained unchanged in PLA (P = 0.433). The tyrosine ratio increased 4.8 fold from baseline in 
LOW, 7.3 fold in MED and 7.3 fold in HIGH.  Individual amino acid data are presented in table 
3. Plasma tyrosine concentration was similar at rest in all trials (P = 0.978). Tyrosine 
concentration increased significantly from rest to P60 in all tyrosine conditions (P < 0.01) and 
then remained elevated between P60 and PTT (P = 0.745). Tyrosine concentration was 
significantly different between PLA and the LOW, MED and HIGH tyrosine doses (P < 0.05). 
Tyrosine concentration was significantly different between LOW and HIGH (P = 0.035) 
although there was no difference between LOW and MED (P = 0.198) or MED and HIGH (P = 
0.792). Amino acids displayed no significant interaction across trials (P = 0.471). Valine (P = 
0.360), leucine (P = 0.253) and isoleucine (P = 0.183) concentrations were similar across all 
trials although did decrease over time in all trials (P < 0.05). Valine decreased significantly from 
rest to PTT in PLA (P = 0.007), (P = 0.015) in LOW and (P = 0.00) in MED. In HIGH, valine 
increased significantly between rest and P60 (P = 0.005) although decreased significantly overall 
between rest and PTT (P = 0.001). Leucine decreased significantly from rest to PTT in PLA (P = 
0.00), (P = 0.004) in LOW and (P = 0.001) in MED. In HIGH, leucine increased significantly 
between rest and P60 (P = 0.001) but decreased significantly overall between rest and PTT (P = 
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0.00). Isoleucine decreased significantly from rest to PTT in PLA (P = 0.00), (P = 0.009) in 
LOW and (P = 0.002) in MED. In HIGH, isoleucine increased from rest to P60 (P = 0.001) but 
decreased significantly overall between rest and PTT (P = 0.004).  The plasma ratio of free (f) 
tryptophan: ∑LNAA was similar at rest between all trials (P = 0.141) although did decrease 
significantly over time in LOW (P = 0.02), MED (P = 0.00) and HIGH (P = 0.00). In PLA, the 
tryptophan: ∑LNAA ratio decreased from baseline to PTT (P = 0.36) although the ratio at all 
time points was significantly different to the tyrosine doses (P < 0.05).  There were no significant 
differences in the f-tryptophan: ∑LNAA ratio between the tyrosine doses (P > 0.05). f-
tryptophan concentration was similar in all trials (P = 0.846) but did change over time in PLA 
and HIGH (P < 0.05). Methionine and phenylalanine remained unchanged from rest across all 
trials (P > 0.05). Decreased concentration in some amino acids comparative to increased tyrosine 
concentration in the tyrosine trials demonstrates the increase in the tyrosine: LNAA ratio was a 
result of these changes. Specifically, overall decreases from rest to PTT in; valine, leucine and 
isoleucine in all tyrosine trials & f-tryptophan in the 400 mg·kg body mass-1 trial led to the 
change in the tyrosine: LNAA ratio.   
 
Blood glucose concentration was similar between all trials (P = 0.623) although was affected by 
time (P = 0.002). Blood glucose decreased significantly from REST to PRE in all conditions (P < 
0.05). Blood glucose rose significantly in LOW between PRE and P60 (P = 0.004). In HIGH, 
blood glucose rose significantly between PRE and P60 (P = 0.039) and then decreased 
significantly between P60 and PTT (P = 0.004). From rest to the end of the time trial, blood 
glucose decreased from 4.5 ± 0.2 to 4.3 ± 0.3 mmol·L-1 in PLA; 4.4 ± 0.3 to 4.3 ± 0.4 mmol·L-1  
in LOW; 4.6 ± 0.2 to 4.2 ± 0.2 mmol·L-1  in MED and 4.5 ± 0.3 to 4.1 ± 0.5 mmol·L-1  in HIGH. 
No significant differences were found in blood lactate concentrations between trials (P = 0.822) 
but were significantly increased over time in all conditions (P < 0.01).  Significant increases in 
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blood lactate were identified between PRE and Post 60 (P = 0.038) and between Post 60 and PTT 
(P = 0.009). From rest to the end of the time trial, blood lactate increased from 0.6 ± 0.1 to 3.3 ± 
1.6 mmol·L-1 in PLA; 0.7 ± 0.3 to 2.9 ± 1.8 mmol·L-1  in LOW; 0.6 ± 0.17 to 3.2 ± 1.3 mmol in 
MED·L-1 and 0.6 ± 0.19 to 3.1 ± 1.4 mmol·L-1 in HIGH.  
 
Plasma volume decreased in a similar fashion following drinks ingestion across all trials (P = 
0.287). From rest to PRE, plasma volume decreased by 2.8 ± 4.6 % in PLA; 1.6 ± 2.1 % in 
LOW; 3.0 ± 1.4 % in MED and 1.0 ± 2.4% in HIGH. Between PRE and Post 60, plasma volume 
continued to decrease by 6.6 ± 5.4 % in PLA; 5.8 ± 2.3 % in LOW; 6.0 ± 3.1 % in MED and 1.2 
± 8.3 % in HIGH (P = 0.76). Plasma volume between Post 60 to PTT demonstrated a continued 
decrease from rest by 9.4 ± 5.5 % in PLA; 7.5 ± 3.7 % in LOW; 9.8 ± 2.9 % in MED and 9.3 ± 













Figure 2. Change in ratio of plasma tyrosine: ∑LNAA (sum of the plasma concentration of 
valine, leucine, isoleucine, methionine, phenylalanine and tryptophan) in the placebo trial 
(PLA), 150 mg·kg (LOW), 300 mg·kg (MED) and 400 mg·kg (HIGH) tyrosine trials. (n = 
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Table 3. Plasma amino acid concentrations  
 
     Values represented as mean (± SD) 
*   Significantly different to REST time point in same trial (P < 0.05)  
** Significantly different to PLA trial at same time point (P < 0.05)  











































































Temperature Measurements   
Friedmans test indicated a gradual increase in core temperature from the start of the 60 minutes 
exercise period to the end of the time trial (P < 0.05) across all trials (Figure 3). There were no 
significant differences in Tcore between trials during the rest period (P = 0.326) or throughout 
exercise (P > 0.05). At the end of the sixty minute exercise period, median Tcore was 38.15 
(1.31) ˚C in PLA; 38.15 (1.19) ˚C in LOW; 37.97 (1.37) ˚C in MED and 38.08 (1.34) ˚C in 
HIGH. At the end of the time trial, median core temperature was 38.49 (1.18) ̊ C in PLA; 38.48 
(1.23) ̊ C in LOW; 38.30 (1.13) ̊ C in MED and 38.37 (1.69) ̊ C in HIGH. Due to technical issues 
mean weighted skin temperature data was available for only five subjects and is presented as 
such.  There were no significant differences in Tskin between trials during the rest period (P= 
0.115). Drink ingestion had no effect on skin temperature across trials during exercise (P = 
0.127) although skin temperature did increase significantly from rest to the end of the time trial 
in all trials (P < 0.05), plateauing after 30 minutes of submaximal, constant intensity exercise. 
Mean weighted skin temperature at the end of the 60 minute period of exercise was 33.76 ± 0.85 
˚C in PLA; 33.77 ± 0.91 ˚C in LOW; 33.74 ± 0.55 ˚C in MED and 33.82 ± 0.85 ˚C in HIGH. 
Skin temperature declined briefly, between the end of the 60 minute submaximal period of 
exercise before increasing again at the start of the time trial across all trials (P < 0.05). Skin 
temperature at the end of the time trial increased significantly from the start of the time trial in 
the LOW, MED and HIGH tyrosine trials (P < 0.05). Skin temperature increased in the PLA trial 
but the increase was not significant (P = 0.105). Mean weighted skin temperature at the end of 
the time trial was 33.38 ± 1.10 ̊ C in PLA; 33.82 ± 1.41 ̊ C in LOW; 33.91 ± 1.03 ̊ C in MED and 






Figure 3.  Median (range) core temperature during the 1 hour rest period, 60 minutes of 
submaximal, constant-load exercise and a simulated time trial.  Time trial data presented 
up to 25 mins (last common time-point when all participants were still exercising) and at 
end of exercise, in the placebo trial (PLA), 150 mg·kg (LOW), 300 mg·kg (MED) and 400 


















































































































































































Figure 4.  Mean (± SD) weighted skin temperature during the 1 hour rest period, 60 
minutes of submaximal, constant load exercise and a simulated time trial. Time trial data 
presented up to 25 mins (last common time-point when all participants were still 
exercising) and at end of exercise, in the placebo trial (PLA), 150 mg·kg (LOW), 300 mg·kg 
(MED) and 400 mg·kg (HIGH) tyrosine trials. (n = 5) * Significantly different from 
SIXTY0 in all trials (P < 0.05)  
 
 
Heart Rate:  
Friedmans test indicated that heart rate increased over time from the start of the 60 minute 
exercise period to the end of the time trial (P < 0.05) although there were no significant 
differences in heart rate between trials at any point (P > 0.05) (Figure 5). Heart rate transiently 
decreased at the end of the 60 minute period of exercise prior to the start of the time trial (P < 















































































































































































PLA; 157 (56) beats·min-1 in LOW; 155 (84) beats·min-1 in MED and 157 (31) beats·min-1 in 
HIGH. At the end of the time trial, median heart rate was 179 (27) beats·min-1 in PLA; 181 (42) 
beats·min-1 in LOW; 184 (49) beats·min-1 in MED and 185 (37) beats·min-1 in HIGH. This 
represented 98 ± 6 %, 97 ± 7 %, 98 ± 8 % and 96 ± 7 % of maximum heart rate in PLA, LOW, 
MED and HIGH respectively. 
 
 
Figure 5. Median (range) heart rate during the 1 hour rest period, 60 minutes of 
submaximal, constant load exercise and a simulated time trial. Time trial data presented up 
to 25 mins (last common time-point when all participants were still exercising) and at end 
of exercise, in the placebo trial (PLA), 150 mg·kg (LOW), 300 mg·kg (MED) and 400 mg·kg 














































































































































































Fluid Intake and Body Mass Losses  
 
Participants consumed similar volumes of fluid in each trial (P = 0.654; 221.3 ± 209.8 mL in 
PLA; 241.75 ± 154.1 mL in LOW; 215.6 ± 174.4 mL in MED and 300.75 ± 237.5 mL in HIGH). 
Body mass losses, calculated as the difference between pre and post body mass, and accounting 
for fluid intake and urine output (collected out-with exercise), was similar across all trials (P = 
0.193; 0.4 ± 0.7 kg in PLA; 0.8 ± 0.6 kg in LOW; 0.5 ± 0.3 kg in MED and 0.5 ± 0.4 kg in 
HIGH). Expressed as a percentage change, body mass losses were similar across trials (P = 
0.495: 0.01 ± 0.006 % in PLA; 0.01 ± 0.007 % in LOW; 0.01 ± 0.006 % in MED and 0.01 ± 
0.006 % in HIGH). Sweat loss was also similar across all trials (P = 0.606; 603 ± 477 mL in 













Subjective Ratings  
Friedmans test demonstrated that RPE increased gradually from start of exercise in all trials (P < 
0.05) although did not differ between trials (P > 0.05) (Figure 6).  Median RPE at the end of the 
60 minute period of submaximal exercise was 14 (5) arbitrary units in PLA; 16 (4) in LOW; 15 
(5) in MED and 15 (4) in HIGH. Median RPE at the end of the time trial was 19 (6) in PLA; 19 
(5) in LOW; 19 (5) in MED and 19 (6) in HIGH. Thermal sensation increased gradually from the 
start of exercise (P < 0.05) although no differences in thermal sensation were found between 
trials (P > 0.05) (Figure 7). Median thermal sensation at the end of the 60 minute period of 
exercise was 5 (6) arbitrary units in PLA; 6 (5) in LOW; 6 (5) in MED and 6 (6) in HIGH. A 
rating between 5 and 6 represents a rating of “Very hot, uncomfortable” on the thermal sensation 
scale. Thermal sensation values at the end of the time trial were similar across all trials (P = 
0.777) with median value of 7 (7) arbitrary units in PLA; 7 (5) in LOW; 7 (5) in MED and 7 (5) 
in HIGH. Thermal sensation at the end of the time trial represented ratings between “Very hot, 













Figure 6. Median (range) rating of perceived exertion values during the 60 minutes of 
submaximal constant load exercise and a simulated time trial. Time trial data presented up 
to 25 mins (last common time-point when all participants were still exercising) and at end 
of exercise, in the placebo trial (PLA), 150 mg·kg (LOW), 300 mg·kg (MED) and 400 mg·kg 





































Figure 7. Median (range) thermal sensation values during the 60 minutes of submaximal 
constant load exercise and a simulated time trial. Time trial data presented up to 25 mins 
(last common time-point when all participants were still exercising) and at end of exercise, 
in the placebo trial (PLA), 150 mg·kg (LOW), 300 mg·kg (MED) and 400 mg·kg (HIGH) 
















































































































































































The present study hypothesized that administration of tyrosine in the medium and high dose 
would enhance exercise performance in the heat based upon tyrosine’s role as a nutritional 
catecholamine precursor.  Despite a firm theoretical basis for the use of tyrosine during exercise 
in the heat, the present study demonstrated that neither the low, medium or high tyrosine dose 
had an effect on exercise performance in the heat, compared to a placebo containing no tyrosine.  
 
Previous studies have examined the effect of a single tyrosine dose on the ability to sustain 
exercise in warm environmental conditions, producing mixed results to date (Tumilty et al., 
2011; Watson et al., 2012; Tumilty et al., 2014; Coull et al., 2015). This is the first study to 
examine the effect of three different tyrosine doses (low, medium and high) on exercise 
performance in the heat. Exercise in the heat should create the stressful environment necessary to 
increase the firing rates of dopaminergic neurons and increase catecholamine synthesis (Powers, 
Howley and Cox, 1982), resulting in a decrease in brain dopamine and precursor availability 
(Fernstrom, 2003; Melamed et al., 1980). Studies by Tumilty et al., (2011) and Tumilty et al., 
(2013) suggest an association between tyrosine availability and exercise tolerance when 
exercising in the heat. Previous studies in animals have demonstrated that increasing the ratio of 
a particular amino acid to its competitors can increase brain uptake (Fernstrom and Wurtman, 
1972; Fernstrom and Faller, 1978) while others have demonstrated that increased precursor 
uptake into the brain can result in increased turnover of that precursor’s neurotransmitter (Brady 
et al., 1980; Acworth et al., 1988). Additional availability of tyrosine, via supplementation, 
should increase transport into the brain and should therefore allow the continued synthesis of 
dopamine during exposure to exercise in the heat. Tumilty et al., (2011) demonstrated tyrosine to 
have a beneficial effect on exercise in warm conditions having reported significant increase in 
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the plasma ratio of tyrosine; competing amino acids, in comparison to a placebo, when exercising 
in the heat. The high and medium dose of tyrosine in the present study was hypothesised to have 
the greatest performance benefit as it would result in the highest increase in the plasma ratio of 
tyrosine: competing amino acids compared to the placebo and low dose, thus transporting more 
into the brain for dopamine synthesis. This hypothesis is supported by the plasma amino acid 
data after tyrosine was administered. The data demonstrate that all three doses of tyrosine 
increased the plasma ratio of tyrosine: competing amino acids significantly in comparison to the 
placebo trial, with the medium and high dose (7.3 fold) increasing the ratio significantly more 
compared to the low dose (4.8 fold). The data does however demonstrate an important finding 
that the medium dose of tyrosine increased the plasma tyrosine ratio to the same extent as the 
high dose, therefore acutely supplementing tyrosine in a dose higher than 300 mg·kg body mass-1 
may be unnecessary.  
 
The importance of dopamine availability during exercise is highlighted by Davis and Bailey 
(1997) who suggest a high ratio of brain dopamine: 5-HT will maintain levels of motivation, 
arousal and drive and subsequently allow exercise to continue. Conversely a high ratio of brain 
5-HT: dopamine is associated with reduced arousal and fatigue (Davis and Bailey, 1997). This 
demonstrates the potential importance of supplying additional tyrosine as a precursor to 
dopamine synthesis, to maintain a high ratio of brain dopamine: 5-HT and thus, prolong exercise.  
Evidence from rat studies demonstrates that fatigue is associated with a reduction in brain 
dopamine synthesis whereas fatigue is delayed when dopamine synthesis and metabolism is 
maintained. Chaouloff et al., (1987) demonstrated that the provision of amphetamines increased 
dopamine activity and potentiated the inhibition of serotonin during exercise in rats. This is 
supported by Yeghiayan et al., (2001) which found, in rats, amphetamine improved forced swim 
test performance following hypothermia. Amphetamine administration is also associated with 
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improved knee extension strength, acceleration, anaerobic capacity and time to exhaustion in 
humans (Chandler and Blair, 1980).  Amphetamines have potent effects on brain dopamine 
release. The mechanisms of amphetamine works similarly to reuptake inhibitors but differently to 
tyrosine in that amphetamine administration increases the release of, and prevents the reuptake 
of, catecholamines at receptor sites (Cooper, 2003). Tyrosine however is tightly regulated by 
tyrosine hydroxylase and may only become effective under stressful conditions (During et al., 
1988; Melamed et al., 1980). In conditions where dopaminergic neurons are not suitably stressed, 
additional tyrosine availability is likely to be affected by end-product inhibition of tyrosine 
hydroxylase (Badaway and Williams, 1982).  The differences in the mechanistic actions of 
tyrosine and other drugs on dopamine synthesis may explain different findings.  Cordery, James, 
Peirce, Maughan and Watson (2016) propose that dopamine release is determined by either the 
cytosolic or the vesicular dopamine pool. L-DOPA induced increases in dopamine release are 
reliant on the vesicular dopamine pool via synaptic vesicle exocytosis and phasic signalling 
(Cordery et al., 2016). The authors suggest that the two pools of dopamine available have a role 
in distinguishing drug actions and individual susceptibility to the effects of particular drugs 
(Cordery et al., 2016). The differences in the effects of phasic and tonic firing of dopamine 
release may explain why catecholamine precursors, such as tyrosine, affect exercise performance 
in a less consistent way in comparison to other drugs such as reuptake inhibitors. Evidence from 
previous studies demonstrates that dopamine reuptake inhibition increases tonic stimulation of 
low affinity postsynaptic receptors and results in desensitization of phasic dopamine signals 
(Dreyer and Hounsgaard, 2013). Tonic dopamine signalling regulates extracellular dopamine and 
is associated with “average reward” of behaviour, therefore when dopamine reuptake inhibitors 
are administered; this can increase motivation and “average reward” which may result in an 
improved performance. The relative success of reuptake inhibitors in improving exercise 
performance (Bridge et al., 2003; Watson et al., 2005) demonstrates this point further. It is 
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possible in the present study that tyrosine administration increased phasic signalling and may 
explain a lack of improvement in exercise performance with tyrosine intake although at present 
this is purely speculative. Despite a sound neurochemical basis for the use of tyrosine as a 
precursor to dopamine in the current study, no performance benefit was found. Regardless of the 
increased availability of tyrosine, it is possible that dopamine synthesis did not increase as the 
nature of the exercise was not appropriate (i.e. not stressful enough) to increase the rate of 
neuronal firing and subsequently deplete tyrosine within brain. As a result, the increase in 
tyrosine availability, as demonstrated by the plasma amino acid data, was likely subject to end 
product inhibition of tyrosine hydroxylase.  
 
Exercise in the heat was assumed to be suitably demanding to stress central catecholamines and 
increase the demand for tyrosine in the brain. Bridge et al., (2003) and Watson et al., (2005) 
highlighted the importance of brain dopamine activity during exercise in warm conditions. 
Bridge et al., (2003) administered a dual 5-HT receptor agonist and a dopamine receptor agonist 
(buspirone) or buspirone and pindolol (a 5-HT receptor antagonist) on two separate occasions 
before exercising to exhaustion in the heat. Results demonstrated that high activity of the 
dopaminergic pathways in the hypothalamus are a predictor of the ability to exercise in the heat 
(Bridge et al., 2003). Furthermore, Watson et al., (2005) administered either placebo or 
bupropion, a dual dopamine/noradrenaline reuptake inhibitor, over four trials prior to exercising 
in both a temperate and warm environment. This study demonstrated that bupropion improved 
time trial performance in the heat but not in a temperate environment. It was demonstrated that 
bupropion, as a dual dopamine/noradrenaline reuptake inhibitor, enhanced exercise performance 
in the heat and allowed subjects to exercise at higher core temperatures when compared to 
temperate exercise where no such effect was recorded. This work demonstrates there to be a 
specific demand for dopamine in the heat which is not present during temperate conditions and 
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should provide the environment necessary to upregulate brain dopamine neurons.  Additional 
tyrosine may then result in an increase in brain uptake, potentially maintaining brain dopamine 
synthesis (Tumilty et al., 2011). Studies by During, Acworth and Wurtman (1989) and Murrin, 
Morgenroth and Roth (1976) have shown that when animals are exposed to stressful treatments, 
such as drug administration to accelerate nigrostriatal firing or electrical stimulation of the 
medial forebrain, brain neurotransmitter turnover increases and tyrosine becomes depleted in 
some neuronal populations. This causes an increased affinity between tyrosine hydroxylase and 
tyrosine which increases dopamine synthesis to maintain dopamine synthesis (Roth, Walters and 
Morgenroth, 1974). In rats, tyrosine administration has been shown to successfully maintain 
catecholamine synthesis and ameliorate behavioural deficits during exposure to tail shock 
(Reinstein et al., 1984), heat stress (Lieberman et al., 2005) and cold swim stress (Brady et al., 
1980). While studies involving cognitive function and tyrosine have produced promising results, 
previous work examining acute tyrosine administration and exercise in the heat in humans have 
been mixed. Furthermore, exercise and tyrosine administration in temperate conditions have 
failed to find any beneficial effect. Watson et al., (2012) suggests an increase in the blood ratio 
of tyrosine: competing amino acids will only prove effective in increasing catecholamine 
synthesis during periods of increased stress over and above that of most exercise conditions, a 
condition not considered to have been achieved in their work. Similarly, Coull et al., (2015) 
found no significant difference between an acute dose of 150 mg·kg body mass-1 tyrosine or 
placebo on time trial load carriage performance test in the heat, despite a marked increase in 
serum tyrosine concentration. Tumilty et al., (2014) found tyrosine to have no performance 
benefit on exercise performance in the heat when a dose of 150 mg·kg body mass-1 was 
administered prior to exercise despite significant increases in the tyrosine ratio to competing 
amino acids. However, an earlier study by the same authors demonstrated that tyrosine had a 
beneficial effect on exercise capacity in the heat. This study demonstrated that a 150 mg· kg 
79 
 
body mass-1 dose of tyrosine increased the ratio of tyrosine to competing amino acids and 
subsequently improved exercise capacity in the heat by 15 ± 11 % in comparison to a placebo.  
To date, this is the only study to show a benefit of acute tyrosine supplementation on exercise in 
the heat.  It is possible that the combination of heat and a performance time trial used in the 
present study was not demanding enough to increase neuronal firing and elicit changes in 
catecholamine metabolism. Therefore, any additional tyrosine availability would have saturated 
tyrosine hydroxylase resulting in end product inhibition (Badawy and Williams, 1982).  
 
When comparing the results of the present study and other studies examining acute tyrosine 
supplementation, there is currently insufficient evidence available to recommend tyrosine prior to 
performing physical exercise in physically stressful and/ or demanding conditions. In 
comparison, tyrosine’s effect on cognition has been shown to be beneficial in a number of 
studies. Evidence suggests tyrosine has a beneficial effect on maintaining cognitive function 
during stress exposure. Tyrosine administration has been shown to improve cognitive function 
during exposure to exercise heat stress (Coull et al., 2014) and improve memory during extreme 
psychological and physical stress (Deijen et al., 1999; Mahoney et al., 2007). Liebermann et al., 
(2014) demonstrated tyrosine to increase feelings of anger in response to acute stress which 
consisted of two mock interrogations during several days of simulated captivity. It was suggested 
that the response of anger was an adaptive emotional response to stressful environments, which 
was enhanced with tyrosine. However the success of tyrosine administration on cognitive control 
may be dependent on individual dopamine function (Jongkees, Hommel and Colzato, 2014). The 
authors suggest individual differences exist in dopamine function, with some carrying the allele 
associated with low prefrontal dopamine function. Individuals with this allele may particularly 
benefit from increased tyrosine availability (e.g. via supplementation) as this may assist in 
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increased conversion of tyrosine to dopamine in the brain. This is a possibility which may be 
considered when designing future research studies involving tyrosine. 
 
It is apparent from the power output values that even pacing was adopted throughout each trial, 
regardless of the amount of tyrosine administered prior to exercise. It was hypothesised that 
tyrosine administration in the medium and high dose would result in faster time trial 
performance, and therefore higher power output during the time trial, in comparison to the low 
dose and placebo. It is obvious that if a pacing strategy was employed by participants during the 
time trial, this was unaffected by tyrosine. St Clair-Gibson et al., (2006) states that the pacing of 
a particular event is influenced by the knowledge of where the endpoint of the activity lies. The 
authors also state that the brain interprets several factors which include the memories of previous 
events of similar distance or duration as well as external factors. These include environmental 
conditions and metabolic factors which together, form an optimal pacing strategy for the 
individual which is necessary in order to avoid catastrophic failure of the task. This may offer an 
explanation as to why Tumilty et al., (2011) found a beneficial effect of tyrosine in a capacity 
trial but found no significant difference in acute tyrosine supplementation when participants 
completed a performance trial (Tumilty et al., 2014). This may demonstrate that tyrosine 
administration is most effective during constant load, submaximal exercise when individualised 
pre-determined power outputs are provided which may be perceived as more physically 
demanding than a self-paced time trial and therefore subjectively more demanding (Tumilty, 
2011). This is supported in work by Lander, Butterly and Edwards (2009) which demonstrated 
that a fixed paced 5000 m time trial on a rowing ergometer resulted in increased levels of blood 
lactate, attainment of a higher core temperature and higher RPE in comparison to self-paced trial 
over the same distance. These differences were observed despite the time taken to complete the 
time trial and power outputs remaining similar throughout both trial conditions.  However, 
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Watson et al., (2012) found no performance benefit from the same dose of tyrosine on exercise 
capacity during a similar protocol with the authors suggesting that the exercise demands were 
insufficient to recognise any performance benefit.  It is plausible to suggest that the exercise 
protocol used in the present study, where participants were free to self-pace the time trial, was 
not physiologically or psychologically demanding enough to elicit increased catecholamine 
metabolism and therefore the additional tyrosine availability was ineffective.  Allowing 
participants to control their power output ‘moment to moment’ may not provide the environment 
necessary to considerably increase dopamine metabolism in comparison to a constant load power 
output which may be interpreted as more physically demanding (Lander, Butterly and Edwards, 
2009). Perhaps a more physically demanding, or longer, exercise protocol may have 
demonstrated a greater effect of tyrosine. In future work, increasing the physical demand of the 
exercise protocol may be achieved through increasing individualised work target quantities 
during the time trial or working at a greater percentage of VȮ2peak during submaximal exercise. 
       
Tyrosine, as a central catecholamine precursor, may act to increase central noradrenaline activity 
and result in reduced exercise performance (Tumilty et al., 2014). This is supported by Roelands 
et al., (2008) who demonstrated that acute administration of reboxetine, a norepinephrine 
reuptake inhibitor, reduced exercise capacity in cyclists in both normal and high ambient 
temperatures. It is thought this occurred because reboxetine exerted both peripheral and central 
effects on the body including accelerations in both resting and exercise heart rate upon 
administration. More than half of the participants also reported feeling cold only when reboxetine 
was administered which may have negatively affected exercise performance.  While not 
statistically significant from any other dose, the present data demonstrate that time trial 
performance in the present study was slowest with the 400 mg·kg body mass-1 dose while the 
150 mg·kg body mass-1 dose and 300 mg kg· body mass-1 were also slower compared to placebo. 
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This may provide support for the explanation that additional tyrosine availability could have 
increased brain noradrenaline activity and therefore reduced exercise performance. Badawy and 
Williams (1982) demonstrated a low dose of tyrosine (20 mg·kg body mass-1) increased cerebral 
catecholamine synthesis whereas higher doses (50 mg·kg body mass-1 up to 500 mg·kg body 
mass-1) were associated with reduced catecholamine levels attributed to feedback inhibition of 
tyrosine hydroxylase activity. Strüder et al., (1998) reported increased plasma prolactin 
concentration as a result of oral tyrosine ingestion suggesting that tyrosine has the ability to enter 
the brain and act centrally. Given that increased dopamine release from the anterior pituitary 
usually inhibits the release of prolactin, this result was somewhat surprising. It is possible that 
the increased availability of brain tyrosine in the Strüder et al., (1998) study may have caused 
feedback inhibition of tyrosine hydroxylase and reduced dopamine synthesis in the pituitary, 
increasing prolactin release.  
 
The present results, and the results from other studies (Tumilty et al., 2014; Coull et al., 2015), 
may demonstrate that exercise in the heat is simply not demanding enough to elicit changes in 
brain catecholamine metabolism such that brain tyrosine availability becomes limiting to further 
catecholamine synthesis. If the stress on subjects was sufficient in these studies, neuronal firing 
would have been increased and catecholamine metabolism maintained. When tyrosine has been 
supplemented to humans in highly stressful situations, it has been shown to reduce deficits in 
cognitive function in studies involving cold exposure (Shurtleff et al., 1994) and very intensive 
military combat training (Deijen et al., 1999). Perhaps the very nature of the stress exposure, be 
it the magnitude, duration or realism of the stressor determines the subsequent effect tyrosine has 
on catecholamine metabolism. Prolonged exposure to stress may deplete catecholamines and 
increase reliance on tyrosine availability. This seems to be particularly evident in studies 
examining cognitive functions dependent upon brain dopamine function, but not as convincing in 
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exercise studies. It is suggested by Cordery et al., (2016) that while fatigue and stress are reduced 
and other cognitive function improved in military based drills with tyrosine supplementation 
(Deijen et al., 1999; Lieberman et al., 2014), the same effects are not commonly found in 
laboratory based settings. This suggests that the psychological and physiological demands 
experienced by military personnel are more demanding compared to that which are experienced 
by participants in a controlled laboratory. This could explain why tyrosine is more effective 
during highly stressful or “real world” environments where the perception of stress is increased. 
 
Similarities in both core temperature and skin temperature between trials demonstrate that 
tyrosine administration had little effect on thermoregulation. Research demonstrates that 
catecholamines may be involved in thermoregulation during exercise (Watson et al., 2005; 
Hasegawa et al., 2008). Watson et al., (2005) demonstrated administration of a 
dopamine/noradrenaline reuptake inhibitor improved tolerance to high core temperatures during 
exercise in the heat. Despite different physiological mechanisms, the study demonstrates 
dopamine availability to have thermoregulatory effects with Hasegawa et al., (2008) finding 
similar results in rats.  Similarly, tyrosine had no effect on heart rate. These findings are 
generally in agreement with much of the literature concerned with exercise following acute 
tyrosine administration (Tumilty et al., 2011; Watson et al., 2012; Tumilty et al., 2014; Coull et 
al., 2015). Unsurprisingly, heart rate increased throughout exercise in the present study, which 
was likely due to cardiovascular strain, caused by heat exposure. This can detrimentally affect 
exercise capacity and performance when demands increase between the active muscles and the 
skin for increased blood flow, both of which require an increased cardiac output (Gonzalez-
Alonso et al., 2003). Performance can be severely affected when this, coupled with decreased 
stroke volume caused by dehydration occurs. However the present study (similarly to others; 
Tumilty et al., 2011 and Tumilty et al., 2014) ensured all participants were provided fluid 
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throughout exercise to avoid excessive dehydration.  The urine osmolality data suggests this was 
effective. Significant increases in core temperature from rest demonstrate subjects were 
hyperthermic at the end of the 60 minute exercise period and at the end of the time trial. 
Morrison et al., (2004) found increasing core temperature resulted in progressively reduced 
voluntary activation during an isometric maximal voluntary contraction despite only moderate 
cardiovascular strain. Increases in these measures appeared to be unaffected by tyrosine 
administration. This suggestion is supported by Tumilty, Davison, Beckmann and Thatcher 
(2014b) which found that administration of 150 mg·kg body mass-1 tyrosine to have no effect on 
central fatigue, measured via peak and sustained handgrip maximal voluntary contraction force in 
hyperthermic subjects. Given that significant rises in both RPE and thermal sensation were 
present across all trials, it is possible to suggest that central fatigue developed as exercise 
progressed (Noakes, 2012; Nybo and Nielsen, 2001) which was likely due to hyperthermia. 
Considering dopamine’s association with increased motivation, arousal, memory, reward 
mechanisms and increased attention (Meeusen et al., 2006), it is perhaps surprising that RPE 
remained similar across all trials. This is despite administration of the medium and high dose of 
tyrosine which were both shown to significantly increase the tyrosine: LNAA ratio in comparison 
to placebo and the low tyrosine dose. Tumilty et al., (2011) demonstrated that subjects exercised 
for significantly longer with 150 mg·kg body mass-1 tyrosine despite similar RPE values 
compared to placebo, suggesting a possible increase in motivation with tyrosine administration. 
This may provide further evidence that the performance time trial was not sufficient to increase 
catecholamine metabolism and may suggest tyrosine to be more effective during an exercise 
capacity trial (Tumilty et al., 2011) where effects on subjective measures and improved exercise 
tolerance have been demonstrated. 
 
While the present study’s protocol was replicated from previously published research, the study 
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contained some limitations which should be considered prior to any further research. As has been 
argued in depth in this discussion, the stress imposed on subjects during exercise may not have 
been substantial to elicit an effect on performance from tyrosine administration. The 
environmental conditions (30°C/60% relative humidity) may not have been demanding enough, 
therefore a future study examining tyrosine doses may benefit from exposing subjects to greater 
environmental stressors. Similarly, the laboratory environment may not be contusive to 
increasing dopamine synthesis with tyrosine administration and may be another limitation of the 
study. Given other previously discussed studies have found tyrosine to be effective in ‘real 
world’ environments, it may be beneficial to administer different tyrosine doses to individuals in 
professions of a more stressful nature (eg. military or hospital settings) to assess any performance 
benefits at different doses. The present work was also limited in that there was no measure of 
dopamine availability following tyrosine administration. As mentioned above, the presence (or 
lack of) of prolactin in the blood is an indicator of decreased/increased dopamine synthesis, 
respectively, and therefore may give a greater indication on the effectiveness of tyrosine 
administration during exercise.      
 
In conclusion, the present study demonstrated that, contrary to the hypothesis, acute 
administration of the catecholamine precursor tyrosine in a low, medium or high dose, had no 
effect on simulated time trial performance in the heat, compared to a placebo containing no 
tyrosine. This is despite significant increases in the plasma ratio of tyrosine: amino acids which 
compete for brain uptake, when tyrosine was administered. The data does demonstrate that the 
medium dose of tyrosine increased the plasma tyrosine ratio to the same extent as the high dose, 
therefore acutely supplementing tyrosine in a dose higher than 300 mg·kg body mass-1 may be 
unnecessary. Despite increases in the tyrosine ratio, it is likely that the exercise protocol and 
environmental conditions were not suitably demanding to increase brain catecholamine 
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metabolism to the extent that brain tyrosine availability became limiting to further catecholamine 
metabolism.  The increased availability of tyrosine may have resulted in feedback inhibition of 
tyrosine hydroxylase within brain neurons.  The main finding of this study is in agreement with 
much of the published literature which has examined acute tyrosine administration and exercise, 
despite a sound neurochemical basis for its use. At present, there is insufficient evidence 
available to recommend that acute oral tyrosine administration is capable of improving exercise 






























The effect of varied tyrosine doses on exercise performance in the heat 
 
Introduction 
Evidence suggests that fatigue during prolonged exercise in the heat may involve factors within 
the brain.  In particular, alterations in chemicals found in the brain may result in increased 
lethargy and sleepiness, which may contribute to fatigue.  Some of these brain chemicals are 
formed by substances called amino acids, and can be altered by the foods we eat.  Consumption 
of the amino acid tyrosine has been shown to increase brain levels of some of these chemicals, 
specifically, dopamine and noradrenaline.  This is particularly relevant because some studies 
suggest that changes in brain dopamine may influence exercise ability in the heat, potentially 
resulting in an improved exercise performance. The majority of previous studies involving 
tyrosine supplementation and exercise in the heat have used the same dose level with some 
showing improved exercise tolerance and others showing no effect. We want to determine 
whether there is an optimal tyrosine dose which enhances exercise in the heat by supplementing 
three different doses of tyrosine. 
 
What is required of me if I agree to take part in the study? 
You will be asked to visit the laboratory on six separate occasions, following an overnight fast. 
We will ask you to drink a pint (or 500 ml) of ordinary tap water two hours before visiting the 
laboratory to ensure that you are properly hydrated.  
During the first visit, we will determine your maximal oxygen uptake value (V ̇O2max), which 
we will use to calculate the appropriate exercise intensity for subsequent visits. This is a maximal 
test where you will be asked to cycle at a fixed rev rate until you fatigue, while the workload gets 
progressively harder, and normally lasts between 10 and 15 minutes.  
A few days after this, you will carry out a familiarisation trial. This trial will be identical to the 
main experiment (with the exception that there will be no blood taken) to allow you to familiarise 
yourself with the procedures and requirements. 
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The main experiment involves the last four visits to the laboratory; each will be separated by at 
least one week.  During each visit we will ask you to provide a urine sample and then weigh 
yourself nude in a separate, private room.  We will then ask you to position a rectal thermometer, 
in private, in order to monitor core temperature.  A Polar heart rate monitor and skin temperature 
probes will also be positioned.  You will then be asked to consume a fruit-flavoured drink 
containing either an amount of tyrosine or a flavoured placebo containing no tyrosine.  Tyrosine 
is a naturally occurring amino acid, it poses no health risk and it has been used in several 
previous studies with no ill-effects.  After drinking the solution, you will be required to sit 
quietly for 1 hour before consuming a second drink, containing the remainder of the tyrosine 
dose, or the placebo. You will then be required to exercise on a cycle ergometer at a moderate 
intensity for 60 minutes, in a warm (30°C, 60% relative humidity) environment. Following 
completion of this you will complete a simulated time trial, where you will be asked to reach an 
individualised work target as quickly as possible. We will measure how hard you feel you are 
working and how hot you feel, every 5 minutes throughout the exercise using simple visual 
scales. Heart rate and core and skin temperature will also be measured every 5 minutes. After the 
exercise, you will give a second urine sample and weigh yourself nude in private. You will be 
free to use the shower and changing facilities in the Department before you leave, if you wish. 
Please allow approximately 3-4 hours for these visits. 
 
Four blood samples, around 10 ml each, will be collected from a forearm vein during each visit 
by a trained individual.  One immediately before you drink the first half of the tyrosine or 
placebo solution, one immediately before you start exercising, one sample after the 60 minutes of 
exercise and a final sample at the end of exercise.  The volume of blood collected will therefore 
be small, about 40 ml in total (3 tablespoons).  
It is important to maintain similar conditions during each trial.  We will therefore ask you to 
refrain from unaccustomed strenuous activity, and avoid drinking alcohol for 24 hours prior to 
each visit.  You will be instructed to complete a 24 hour food and exercise diary prior to the first 
visit and you should consume foods of similar quantity and nature before the second visits. 
Can I change my mind if I decide I no longer want to take part in the study? 




Should you have any further questions regarding participation in the study, I will be pleased 
to answer them, and may be contacted on: 




If you have any complaints about any aspect of this study you can contact: 
Academic Supervisor: Dr Les Tumilty, email: llt07@aber.ac.uk, tel: 01970628425  

































The effect of varied tyrosine doses on exercise performance in the 
heat 
 




PRINCIPAL INVESTIGATOR: Nick Gregory 
 
ADDITIONAL INVESTIGATORS: Dr Les Tumilty, Dr Rhys Thatcher 
 
 
I have read the volunteer information sheet on the above study and have had the opportunity to discuss the details 
and ask questions.  The investigator has explained to me the nature and purpose of the tests to be undertaken.  I 
understand fully what is proposed to be done. 
 
I have agreed to take part in the study as it has been outlined to me, but I understand that I am completely free to 
withdraw from the study at any time I wish.  
 
I understand that these trials are part of a research project designed to promote scientific knowledge, which has been 
approved by the Institute of Biological Environmental and Rural Sciences Ethics Committee, and may be of no 
benefit to me personally.   
 
I understand that participation in the research project involves maximal intensity exercise on a number of occasions 
 
I understand that participation in the research study involves multiple blood samples being taken 
 
I understand any data collected will be kept confidential, and only be seen by principal investigator and supervisor.  
 
I hereby fully and freely consent to participate in the study which has been fully explained to me.  
 
 
SIGNATURE OF VOLUNTEER: .............................................…...................... 
 
          
     Date: ........................... 
 
I confirm that I have explained to the volunteer named above, the nature and purpose of the 




SIGNATURE OF INVESTIGATOR: .................................................................. 
                                                                                                Date : ......................... 
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Participate in an exercise 
study and receive a free 
fitness test! 
Want to find out how fit you are? 
The Institute Biological, Environmental and Rural 
Sciences at Aberystwyth University are looking for 
men who are fit and healthy, aged 18 – 45 and who 
exercise regularly to take part in a study.  We will 
be exploring a potential performance enhancing 
nutritional supplement during cycling in the heat 
What do you get for participating? 
We will give you an accurate measurement of your aerobic 
fitness level (V̇O2max) as well as the opportunity to ask 
advice on sports nutrition and training.  
 
Contact 
 For further information please contact 








Aberystwyth University Ethics Committee for 
Research Procedures 
ECRP06: Postgraduate Research Assessment Form 
 
 
For all PhD and Master’s research involving human subjects or human tissue. 
 
Section A: To be completed by the Postgraduate Student 
 
Proposed Research Title: The effect of different dosages of tyrosine on exercise performance in 
the heat 
 
Student Name: Nicholas Gregory  
 
Supervisor(s): Dr Les Tumilty, Dr Rhys Thatcher 
 
Source of Funding: Self-funded  
 
Start of MPhil Registration: September 2014 
 
Please outline briefly the focus and purpose of your proposed research:  There is a large 
body of evidence which demonstrates that exercise performance is impaired in hot and humid 
conditions compared to cooler conditions. A number of studies have assessed the effectiveness of 
tyrosine supplementation on the ability to complete a prolonged period of exercise in a hot 
condition. Tyrosine is a major physiological amino acid precursor to brain dopamine. It is 
suggested that a high ratio of brain dopamine extends prolonged exercise while conversely 
stating that when dopaminergic activity is reduced, fatigue is precipitated by a loss of motivation 
and arousal (Davis and Bailey, 1997), particularly during prolonged exercise in the heat (Watson 
et al., 2005).  
 
Tumilty et al. (2011) demonstrated that acute supplementation of tyrosine (150 mg kg body 
mass-1) was associated with increased endurance capacity in the heat. However, a separate study 
by Tumilty, Davison, Beckmann and Thatcher (2014) indicated that the same acute dose of 
tyrosine failed to influence endurance performance in the heat.  These conflicting results could be 
due to the adoption of an insufficient tyrosine dose under the more physiologically demanding 
conditions of a performance trial, compared to a capacity trial.  No study has examined the effect 
of different tyrosine doses on exercise performance in the heat. Therefore, the purpose of this 
investigation is to administer different doses of tyrosine to ascertain which dose, if any, enhances 
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exercise performance in the heat.  It is intended that the results of the study will assist in 
identifying the effectiveness of tyrosine supplementation, specifically highlighting what the 
optimum dose is. The study will also advance current understanding and knowledge in this field 
and will provide further insight in to the mechanisms which limit exercise and/or work tolerance 
under extreme environmental conditions. 
 
 
Please outline briefly the methods that you propose to employ in the research: 10 
participants will visit the laboratory on 6 separate occasions. The first two visits will consist of a 
ramp test, to establish maximal oxygen uptake, followed by a familiarisation trial, to accustom 
subjects to future trials and appease any concerns they may have.  These will be separated by at 
least 48 hours. The following four visits will be experimental trials and will be separated by at 
least 7 days. The experimental trials will consist of a placebo trial in which a sugar-free drink 
with microcrystalline cellulose (a calorie-free food constituent) will be administered, and three 
trials in which the same sugar-free drink will be administered, with one of three different doses 
of tyrosine (150, 300, 400 mg kg body mass-1 tyrosine). The order of these trials will be 
completed in a randomised, crossover fashion and the tyrosine and placebo drinks will be 
administered in a double-blind fashion.  On arrival at each experimental trial, subjects will be 
required to provide a blood sample (acquired by a standard venepuncture method) before being 
given a drink containing 300 ml of sugar-free fruit flavoured squash and ordinary tap water with 
either half the total dose of tyrosine or a placebo (same drink volume with a small amount of 
microcrystalline cellulose). Following ingestion of the drink, subjects will be required to sit 
quietly for one hour, provide a second blood sample, before consuming a second 300 ml drink 
containing either the remainder of tyrosine or placebo dose. Subjects will then cycle for 60 
minutes in the heat at 10% Δ, which is a moderate intensity and will be well within the 
capabilities of each participant. At the end of the 60 minute period of cycling, participants will 
provide a third blood sample before completing a simulated time trial, requiring completion of an 
individualised target work quantity, lasting approximately 20 – 25 minutes. Following 
completion of the time trial, participants will provide a fourth blood sample. All exercise will be 
completed within the environment chamber at a temperature of 30°C and 60% relative humidity. 
Heart rate, core temperature, skin temperature, RPE and thermal sensation values will be 
recorded throughout each experimental trial. Core temperature will be monitored every 5 minutes 
throughout the cycle exercise. Skin temperature at four sites (via skin thermistors) will also be 
recorded every five minutes throughout the rest and cycle exercise periods, and recorded using an 
electronic data logger. Heart rate will be recorded every five minutes throughout the resting and 
exercise periods using radiotelemetry. Ratings of perceived exertion will be assessed every five 
minutes throughout exercise using a validated visual analogue scale (Borg, 1982).  Thermal 
sensation will also be assessed after every five minutes of exercise using a separate visual 
analogue scale (Parsons, 2002). 
 
 
Please complete the following checklist: 
Does the research involve participants under the age of 
18? 
 
YES NO N/A If yes, refer to 
ECRP 
If yes, is the involvement of children central to the 
research? 
YES NO N/A If yes, please 
justify1 
                                                          
1 Where research can be confined to adults without detrimental effect, children should not be involved. If the 
investigators feel that children are essential to the research, this should be justified in the research proposal 




If children are involved, will access to participants be 
obtained through appropriate and responsible 
gatekeepers? 
 
YES NO N/A  
If yes, will access to participants be obtained through 
appropriate and responsible gatekeepers? 
 
YES NO N/A  
Will consent be sought from both children and 
parents? 
 
YES NO N/A  
Does the research involve other vulnerable 
participants? 
 
YES NO N/A If yes, refer to 
ECRP 
If yes, is the involvement of vulnerable participants 
central to the research? 
 
YES NO N/A If yes, please 
justify2 








If yes, is the involvement of students central to the 
research? 
 
YES NO N/A If yes, please 
justify3 
Does the proposal involve covert research? 
 
YES NO N/A If yes, refer to 
ECRP 
If yes, are you confident that data cannot be obtained 
through non-covert methods? 
 
YES NO N/A  
Will the research participants be fully informed about 
the purpose of the research? 
 
YES NO N/A See attached 
participant 
information sheet 
Will the informed consent of the research participants 
be obtained? 
YES NO N/A See attached 
informed consent 
agreement 
Will anonymity be extended to all research 
participants? 
 
YES NO N/A  
If not, will participants be informed of this? 
 
YES NO N/A  
Is it clear to participants that they can withdraw at any 
time?  
 
YES NO N/A  
Is it clear to participants that their data does not enjoy YES NO N/A  
                                                          
2 Where research can be confined to non-vulnerable participants without detrimental effect, vulnerable 
participants should not be involved. If the investigators feel that vulnerable participants are essential to the 
research, this should be justified in the research proposal submitted to the ECRP. 
3 Where research can be confined to non students without detrimental effect, students should not be involved. If 
the investigators feel that students are essential to the research, this should be justified in the research proposal 





Have arrangements been made to ensure that 
guarantees of confidentiality and anonymity can be 
honoured? 
 
YES NO N/A See ECRP7 form 
If data is to be shared with other researchers in the 
future, will the consent of participants be sought? 
 
YES NO N/A  
Will appropriate measures be put in place for the 
secure and confidential storage of data? 
 
YES NO N/A See ECRP7 form 
In the case of elite-level interviews, will consent be 
sought for the attribution of quotes and data? 
 
YES NO N/A  
Will the research expose participants to physical or 
psychological conditions different to those experienced 
in everyday life? 
 
YES NO N/A See ECRP7 form 
Have measures been put in place to minimise or 
alleviate any distress which the research may cause? 
 
YES NO N/A See ECRP7 form 
Does the proposal involve research via the internet? 
 
YES NO N/A Please provide 
details 
Does the proposal involve interviews or 
questionnaires? 
 
YES NO N/A  
In the case of fieldwork, has a risk assessment been 
produced? 
 
YES NO N/A  
In the case of action research, evaluation and 
consultancy, are measures in place to ensure balanced 
participation? 
 
YES NO N/A Please provide 
details 
In the case of externally funded research, have the 
respective obligations of the researcher and funding 
body been clarified? 
 
YES NO N/A Please provide 
details 
Have the rights of researchers to disclose the aims and 
background of the project, and to publish and 
disseminate results been clarified? 
 
YES NO N/A See ECRP7 form 




YES NO N/A If no, project should 
not be undertaken 
Will participants be consulted prior to publication? 
 
YES NO N/A  
Will final project reports be made available to 
participants? 




Do you believe that the proposed research complies 
with AU’s Template for Research Involving Human 
Tissue or Participants? 
YES NO N/A If no, please explain 
below 
 
Student’s signature:  
__________________________________________________________________ 




Section B: To be completed by the Director of Research/Director of Postgraduate Studies 
This checklist is designed to assist the Director of Research/Director of Postgraduate Studies in 
the process of deciding whether a proposal satisfies AU’s Template for Research Involving 
Human Tissue or Participants.  If the answer to any of the questions is negative or doubtful, the 
project should be sent back to the Principal Investigator or referred to the University Ethics 
Committee for Research Procedures.  If in any doubt please contact the Secretary of the 
Committee in the Deans’ Office.  
Is the research proposal of good design? YES NO N/A  
Are arrangements for the supervision of the project appropriate? YES NO N/A  
Is the research carried out or supervised by competent 
researchers? 
YES NO N/A  
Do the foreseeable benefits of the research outweigh the 
foreseeable risks? 
YES NO N/A  
Does the proposed research pose only minimal and predictable 
risk to the researcher? 
YES NO N/A If no, refer to 
ECRP 
Does the proposed research pose only minimal and predictable 
risk to the research subject? 
YES NO N/A If no, refer to 
ECRP 
Does the research proposal include sufficient and appropriate 
procedures to obtain the informed consent of the research 
subjects? 
YES NO N/A  
Is it clear to the subjects that they may withdraw at any time? YES NO N/A  
Have arrangements been made to ensure that material obtained 
from or about a subject remains confidential? 
YES NO N/A  
Where the proposal involves interviews and/or questionnaires, 
are measures in place to monitor interview structures 
and/questionnaire design? 
YES NO N/A  
 













If the proposal involves vulnerable participants, is sufficient 
justification provided? 
YES NO N/A  
Does the research proposal comply with the Template for 
Research Involving Human Tissue or Participants? 
YES NO N/A If no, please 
explain below 
(For research proposals to be referred to the University Ethics 
Committee for Research Procedures) Have forms ECRP01 
and ECRP02 been completed? 
YES NO N/A  
 




___________________________________________________________________________                   
Date:  04.12.14_________________________ 
 
If the proposed research is judged to comply with the University’s Template for Research 
Involving Human Tissue or Participants, indicate whether you feel it to be level one or two, and 
retain a copy of this form for the Department’s report to the University’s Ethics Committee for 
Research Procedures. 
 
If the proposal involves covert research, subjects under the age of 18, vulnerable participants, or 
exposes participants to any physical or psychological conditions different to those experienced in 
everyday life and does not incorporate steps to control or minimise these conditions, and/or the 
researcher has not demonstrated the necessary skills and understanding, and/or the project does 
not fulfil all legal and university regulations, indicate which of the levels detailed in the 
Statement for Research Council you consider it to merit and submit further details of the project 
on Forms ECRP01 and ECRP02 to the Secretary of the University Ethics Committee for 
















Aberystwyth University Ethics Committee for Research 
Procedures 
 
Application for Approval of Experiment and  





This form does not need to be submitted for proposals which have met the criteria set under 
the generic protocols approved by each department, and are reported annually to the 
University Ethics Committee for Research Procedures. 
 
This form is to be used in conjunction with form ECRP02. Please complete both forms 
and return to  
 
Section A: Brief details of the Application 
 




2. Name of Principal Investigator(s): [attach a statement of their qualifications and 
prior experience, which are relevant to the proposed project] 
 
Title: Mr Forename: Nick   Surname: Gregory Qualification: BSc 
 
 
Research student leading to an MPhil qualification, IBERS, Aberystwyth University, 
Aberystwyth  






Title: Dr                 Forename: Les   Surname: Tumilty Qualification: PhD. 
 
Personal experience of the proposed protocol, and several years of experience with similar 





3. Department(s) involved:  
IBERS, Aberystwyth University, Aberystwyth. 
 
 
 4. Names and status of any other members of staff involved:  
Title: Dr  Forename:  Rhys      Surname: Thatcher Qualification: PhD 
  
 
Personal experience of the proposed protocol, and several years of experience with similar 













6. Will any part of the investigation be carried out under the auspices of an outside 






7. Will students be involved in carrying out the investigation? 
 
 Yes, the research will be carried out as partial requirement of an MPhil qualification.  
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Section B: Abstract of Project (Continue on a separate sheet if necessary) 
 
 
1. What is the purpose of the investigation? Is it intended to benefit the subject? 
 
There is clear evidence that exercise is impaired in hot and humid environments compared to 
cooler climates (Tatterson, Hahn, Martin and Febbraio, 2000; Gonzalez-Alonso, Teller, 
Andersen, Jensen, Hyldig and Nielsen, 1999; Galloway and Maughan, 1997). The impairment of 
exercise in the heat has been associated with increased central fatigue which is defined by Nybo 
(2010) as an impaired ability to sustain muscle activation and increased subjective effort during 
exercise. It is suggested by Davis and Bailey (1997) that altered brain neurotransmitter activity 
may account for this fatigue.  Specifically, a high ratio of brain dopamine to brain serotonin is 
suggested to sustain motivation and arousal during prolonged exercise and a low ratio induces 
central fatigue. This is particularly relevant to prolonged exercise in the heat as the maintenance 
of brain dopamine activity appears to specifically influence the ability to continue exercise 
(Watson et al., 2005).  The amino acid tyrosine is a major nutritional precursor to brain dopamine 
(Glaeser, Melamed, Growdon and Wurtman, 1979). Tumilty et al. (2011) demonstrated that acute 
supplementation of tyrosine (150 mg kg body mass-1) was associated with increased endurance 
capacity in the heat. However, a separate study by Tumilty, Davison, Beckmann and Thatcher 
(2014) indicated that the same acute dose of tyrosine failed to influence endurance performance 
in the heat.  These conflicting results could be due to the adoption of an insufficient tyrosine dose 
under the more physiologically demanding conditions of a performance trial, compared to a 
capacity trial.  No study has examined the effect of different tyrosine doses on exercise 
performance in the heat. Therefore, the purpose of this investigation is to administer different 
doses of tyrosine to ascertain which dose, if any, enhances exercise performance in the heat.  
 
The exercise protocol adopted is identical to one used previously in our laboratory (Tumilty et al. 
2014).  It is intended that the results of the study will assist in identifying the effectiveness of 
tyrosine supplementation, specifically highlighting what the optimum dose is. The study will also 
advance current understanding and knowledge in this field and will provide further insight in to 
the mechanisms which limit exercise and/or work tolerance under extreme environmental 
conditions. The results will have potential application to several areas in which physical work is 
performed in warm/hot environments such as armed and uniformed services, sport and manual 
labour intensive employment. 
 
Direct benefit to the participants will include the use of exercise equipment and expertise within 
the sport and exercise science building, including fitness testing which will enable the 
identification of an individual’s aerobic fitness (V̇O2 peak).  Also, as some participants will be 





2. Will invasive procedures (medical or surgical) be used? 
 
Blood samples will be taken from an arm vein (by a standard venepuncture method) during each 
visit by suitably trained staff: one before participants are given the supplement, another sample 
one hour after drink ingestion, immediately before they start exercising, one sample after cycling 
for 60 min, and a final sample when they stop exercising at the end of the time trial.  The total 
112 
 
amount of blood sampled during each visit will be minimal, approximately 40 ml, or 3 
tablespoons.   
 
A rectal thermistor, positioned 10 cm beyond the anal sphincter will be used to record core 
temperature, as per RA SES9.  This is a common method of core temperature measurement in 
these types of investigations which poses no health risk to the participant.  The thermistor is 
thoroughly sterilised following each use, and sealed in a protective bag between visits, as per 
SOP SES5. 
 
3. In the course of the investigation, might pain, discomfort (including psychological 
discomfort), inconvenience or danger be caused?  
 
Blood sampling carries a small risk of bruising or infection, but only trained staff obtain samples 
and with good practice, any risk is minimal.   
 
Exercising in a warm environment can cause dizziness or light headedness in some individuals, 
however with constant monitoring of core temperature as well as staff being vigilant at all times, 
the risk is minimal.  If participants feel unwell at any time they are free to stop exercising should 
they wish to do so.  Also, the proposed participant population will be familiar with the 
discomfort associated with strenuous exercise.    
 
The use of the tyrosine drink poses no health risk and has been used in several previous studies 
with no ill-effects (Shurtleff et al., 1994; Strüder et al., 1998; Chinevere et al., 2002; Mahoney et 
al., 2007; Tumilty et al., 2011; Tumilty et al., 2014).   
 
 
 4. Give details of the proposed research protocol including equipment to be used and any 
safeguards or precautions to be taken. Include a statement of the findings of any risk 
analysis undertaken with regard to the subject’s safety and well being. 
 
Participants will initially complete an incremental exercise test on a cycle ergometer to measure 
their peak oxygen uptake ( V O2peak), using a computer analysis system for breath-by-breath 
analysis.  The incremental exercise test will involve subjects breathing through a mouthpiece, 
which will be sterilised between each visit (this procedure is covered under the Department’s 
generic physiology procedures and risk assessments). 
 
Following this, participants will complete a familiarisation visit to accustomize themselves with 
the procedures and environmental conditions as well as the sampling protocol.  This will be 
identical to the placebo trial, including administration of the placebo drink.  Finally, four main 
visits will be carried out which will be similar in every respect to the familiarisation visits, except 
in three of these trials, tyrosine will be administered in three different doses, as opposed to the 
placebo drink.   
 
Each of these visits will require participants to arrive at the lab in the morning after an overnight 
fast of at least 8 hours.  Nude body mass will be assessed and a urine sample will be taken in 
order that urine osmolality can be measured (to ensure that they are hydrated prior to beginning 
exercise). If participants are hypohydrated (urine osmolality > 700 milliosmoles per kg; ACSM, 
2007), then testing will be rescheduled. A blood sample will be taken from an arm vein by a 
standard venepuncture method. Participants will then be required to ingest one of four drinks in a 
randomised, double-blind fashion: 300 ml of lemon and lime flavoured sugar-free squash and 
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ordinary tap water with the addition of either half of the prescribed experimental dose (150, 300 
or 400 mg per kg body mass tyrosine), or the same volume of fluid containing a small amount of 
microcrystalline cellulose (as placebo). Following ingestion, participants will be required to sit 
quietly for one hour, after which they will consume the remaining half of the prescribed 
experimental tyrosine dose or the placebo in a further 300 ml of sugar-free squash and ordinary 
tap water.  They will give a second blood sample, before entering the heat chamber (30°C and 
60% relative humidity) to commence exercise. The initial bout of exercise will require 
participants to exercise for 60 minutes at a power output equivalent to 10% Δ (power outputs are 
calculated individually for each participant with data derived from the previous ramp test). This 
is a moderate intensity and is well within the abilities of healthy individuals.  The 60 minutes of 
cycling will then immediately be followed by a third blood sample before a self-paced cycling 
time trial is completed where participants will be required to complete a set amount of work as 
quickly as possible. The set amount of work will be individualised to each participant, calculated 
based upon the data from the initial ramp test, and will last approximately 20 to 25 minutes.  A 
fourth blood sample will be taken upon completion of the time trial.  
 
Core temperature will be monitored every 5 minutes throughout the cycle exercise in accordance 
with the departmental risk assessment for exercise in the environmental chamber.  Skin 
temperature at four sites (via skin thermistors) will also be recorded every five minutes 
throughout the rest and cycle exercise periods, and recorded using an electronic data logger. 
 
Heart rate will be recorded every five minutes throughout the resting and exercise periods using 
radiotelemetry. 
 
Ratings of perceived exertion will be assessed every five minutes throughout exercise using a 
validated visual analogue scale (Borg, 1982).  Thermal sensation will also be assessed after every 
five minutes of exercise using a separate visual analogue scale (Parsons, 2002). 
 
Standard statistical methods will be used to analyse data.  For example, a repeated measures 2-
way ANOVA (time × trial) will be used to analyse differences between the placebo and 
experimental conditions. Time to complete the time trial will be analysed using a 1-way repeated 
measures ANOVA.  Data will be analysed at a significance level of 0.05.  
 
 
5. What will be the duration and frequency of the procedures? 
 
At least 48 hours will separate the initial incremental cycle test and the first familiarisation visit, 
and at least seven days will separate each of the familiarisation and main visits.  The incremental 
test will be completed in around 30- 45 minutes, and the familiarisation and main visits will 
require approximately 3-4 hours for each visit. 
 
 
6. What steps will be taken to safeguard against the effects of any repetitive research? 
 
Adequate rest will be given to ensure complete recovery between visits.  Also, participants will 
refrain from unaccustomed strenuous activity for 24 hours before each visit. Participant numbers 
are small so it is unlikely that repetitive research will take place within the study. A secure 
database will be held (along with screening questionnaires- in accordance with departmental 





















 Section C: Information on Subjects  
 
NB: No subject should be admitted to a trial before the University Ethics Committee for 
Research Procedures has issued its written approval. 
 
 
1. How many subjects will be involved? 
 
10 participants will be adequate to highlight any effect of the proposed drink on exercise 
performance.  A previous study in our laboratory using 8 subjects was adequate to identify an 
increase in exercise time to exhaustion in the heat at a constant-load, submaximal intensity (i.e. 
exercise capacity as opposed to performance), between a tyrosine-containing drink (150 mg kg 
body mass-1) and placebo drink containing no tyrosine, with an effect size of 0.63 and a resultant 
statistical power value of 0.78.    
 
 
2. What is the age and sex of each? 
 
It is envisaged that the majority of participants will be physically active males recruited from the 
student and staff populations of Aberystwyth University, as well as local sporting clubs.  The age 
range of participants will be 18 – 45.  Because of the physically demanding nature of the study, 
anyone with a history or predisposition to musculoskeletal, or cardiorespiratory, or metabolic 
disease will be excluded. 
 
 
3. How are the subjects to be recruited? Provide  
(i) a copy of the advertisement/letter of invitation to be used and 
(ii) a copy of the information sheet4 given to subjects. 
 
                                                          
4 The information sheet and the informed consent may include similar text.  The distinction is that the 
information sheet is something the participant can take away.  The informed consent is something the individual 
signs and is kept by the researcher. 
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Subjects will be recruited by means of posters around the University campus and by weekly e-
mail bulletin distributed by the University Information Services and also via the sports and 
activities officer within Aberystwyth University. 
 
 
4. How and when will their consent be obtained? Provide a copy of the informed consent 
form to be used.5 
 
Informed consent will be obtained following an initial meeting with potential participants, during 
which all potential risks and discomforts associated with the study will be outlined.  Verbal and 
written informed consent will be obtained from all participants before any testing takes place in 
line with the departmental generic ethics document. 
 
 
5. How will the subject’s physical and mental suitability for participation be assessed? 
 
A health questionnaire will be completed by all potential participants at the initial meeting with 
investigators, and also during each visit to the laboratory, before exercise commences, to assess 








7. What steps, if any, will be taken to safeguard the confidentiality of the results of the 
investigation? 
 
Participants will be assigned a code on commencing the study, and will only be identifiable by 
name to the study investigators.  All collected data will be stored securely within the department 
on password protected PCs, and will not be shared with outside parties without prior consent 
from the individual concerned. 
 




9. Any further relevant information. 
None. 
                                                          
5 This must detail the basic purpose of the study, a fair explanation of what the participant will do, the risks and 
benefits, and a statement that the participant may withdraw at any time without prejudice.  Since participants 
may commonly be students, where appropriate there should be a statement that involvement in or withdrawal 
from the project will have no implications to their academic standing within the university.  
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Section D: Declaration 
 
The following declaration should be signed by the Principal Investigator(s) and the relevant Head 
of Department. 
 
I certify that to the best of my knowledge the information given above, together with any 
accompanying information, is complete and correct and I approve the application for submission 





 Date  
Head of Department  Date  
 
Encs: (tick box to indicate that relevant document is attached) 
 
(i) Statement of Principal Investigator(s) relevant qualifications and prior 
experience 
                                                                                            
(ii) Proposed advertisement/invitation to recruit subjects 
                                                                                            
(iii) Proposed information sheet for subjects 
                                                                                            
(iv) Proposed informed consent form 
                                                                                            
(v) Proposed sample letter to subject's GP 
 
(vi) Form ECRP02 
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